Review

Lead radionuclides for theranostic applications in nuclear medicine: from atom to bedside

Yani Berckmans[1], Janke Kleynhans[2], Sara Van Mechelen[1,3], Karolien Goffin[4], Kristof Baete[4], Michel Koole[4], An Coosemans[1], Thomas Elias Cocolios[5], Christophe M Deroose[4], Yann Seimbille[6,7], Frederik Cleeren[2✉]

1. KU Leuven, Department of Oncology, Laboratory for Tumor Immunology and Immunotherapy, Leuven Cancer Institute, Leuven, 3000, Belgium.
2. KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Laboratory for Radiopharmaceutical Research, Leuven, 3000, Belgium.
3. Belgian Nuclear Research Centre (SCK CEN), Radiobiology Unit, Nuclear Medical Applications Institute, Mol, 2400, Belgium.
4. KU Leuven, Department of Imaging and Pathology, Nuclear Medicine and Molecular Imaging, Leuven, 3000, Belgium.
5. KU Leuven, Department of Physics and Astronomy, Institute for Nuclear and Radiation Physics, Leuven, 3001, Belgium.
6. Department of Radiology and Nuclear Medicine, Erasmus MC, 3015 CN Rotterdam, The Netherlands.
7. Erasmus Medical Center Cancer Institute, 3015 GD Rotterdam, The Netherlands.

✉ Corresponding author: frederik.cleeren@kuleuven.be.

Abstract

Lead-212 has emerged as a promising radionuclide for targeted alpha therapy (TAT), positioning itself at the forefront of next-generation cancer treatments. What sets lead-212 apart is its unique decay profile: while it is a beta emitter, it mainly serves as an *in vivo* generator of the potent alpha-emitting daughter radionuclide bismuth-212. This characteristic offers a versatile radiobiological profile, potentially optimizing therapeutic efficacy by combining the radiochemical characteristics of lead-212 such as easy radiolabeling and practical half-life, with the therapeutic benefit of alpha particles. The relatively short half-life of lead-212 (10.6 hours) offers favorable dosimetric properties, enabling effective treatment while minimizing long-term radiation exposure. Its gamma-emitting analogue, lead-203, is well-suited for single-photon emission computed tomography (SPECT) imaging, forming an ideal theranostic matched pair that can significantly accelerate preclinical and clinical research. Crucially, the generator-based production of lead-212 enables decentralized and on-demand availability, but its half-life also allows centralized production, facilitating broad clinical access and logistical flexibility. In this review, the advantages and challenges of lead-based radiopharmaceuticals are discussed, covering the entire chain from radionuclide production to bedside administration. Special attention is given to the coordination chemistry of lead, and we give an overview of available bifunctional chelators. We also present the latest advancements in preclinical and clinical applications and conclude with perspectives on future directions of lead-based theranostics.

Keywords: lead-212, lead-203, radionuclide therapy (RNT), targeted radionuclide therapy (TRT), targeted alpha therapy (TAT), single-photon emission tomography (SPECT)

Introduction

As the global pursuit of precision cancer therapies accelerates, alpha-emitting radionuclides are gaining increased attention for use in radionuclide therapy (RNT), although ensuring sustainable and widespread access to these powerful agents remains a critical challenge [1]. Lead-212, with its generator-based production methods and alpha-emitting decay chain, offers a unique solution to these supply constraints and could pave the way for a broader clinical adoption of targeted alpha therapy (TAT) [2]. The raw materials required to produce lead-212, such as thorium-228 derived from legacy nuclear sources,

are reported to be in ample supply [3]. Furthermore, the dual functionality offered by the lead-203/lead-212 theranostic pair will allow for the quantification of the biological behavior of the radionuclide during the translational phase [4].

Historically, diagnostics and therapeutics in medicine have evolved as separate disciplines, often operating in parallel rather than synergistically. Nuclear medicine, however, offers a distinct advantage through the concept of *theranostics*, which aligns closely with the principles of precision medicine. This approach enables both diagnosis and

treatment using the same molecular target. Diagnosis is typically achieved through non-invasive molecular imaging techniques such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT), which first confirms that a specific biological target is present in sufficient quantity within the tumor. Following initial identification, the diagnostic non-cytotoxic radionuclide may be exchanged for a therapeutical cytotoxic analogue, utilizing an analogous molecular vector. This theranostic approach allows selective irradiation of the malignancy depicted in the initial molecular imaging scan [5]. Prominent examples of theranostics include targeting prostate-specific membrane antigen (PSMA) in castration-resistant prostate cancer, where the therapeutic radiopharmaceutical is [^{177}Lu]Lu-PSMA-617 (United States Food and Drug Administration (FDA) approved as Pluvicto® in 2022), and somatostatin receptors (SSTRs) in neuroendocrine tumors (NETs), with [^{177}Lu]Lu-DOTA-TATE (FDA approved as Lutathera® in 2018) as the therapeutic partner [6–8]. In these cases, diagnostic radiopharmaceuticals using PET radionuclides such as gallium-68 or fluorine-18 can serve as the diagnostic counterparts [6-8].

While these beta-minus (beta-) emitting theranostic approaches have demonstrated substantial clinical benefit, they are not without limitations. The relatively low linear energy transfer (LET) of beta-particles is still insufficient to deliver a lethal dose to the tumor cells in current clinical applications. Their cytotoxicity therefore relies heavily on the presence of oxygen to generate reactive oxygen species. Additionally, resistance can arise through mechanisms such as upregulated DNA repair pathways and reduced sensitivity to radiation-induced DNA damage [9]. In contrast, alpha particles are highly cytotoxic due to their high LET, resulting in the deposition of energy over a very short path length in biological tissue, typically spanning just 2 to 10 cell diameters. This concentrated energy delivery causes dense ionization tracks that lead to complex and clustered DNA damage, including double-stranded DNA breaks, which are often difficult to accurately repair, increasing the likelihood of lethal outcomes such as apoptosis or mitotic catastrophe. Moreover, in hypoxic conditions, alpha emitters maintain their effectiveness due to their direct ionization mechanism, making them less dependent on the oxidative status of malignant lesions [9,10]. An additional benefit of alpha emitters is the amplified cytotoxicity through effective activation of the immune system which might incorporate bystander and other systemic responses. TAT is consequently highly effective against hypoxic

and radioresistant disease, both in micro-metastases as well as larger tumors [9,10].

Despite encouraging initial clinical outcomes, the search for the optimal alpha-emitting radionuclide remains ongoing. When the respective nuclear properties are considered, eight alpha emitters have been identified as promising potential candidates for clinical translation [11]. However, many of these radionuclides face significant production and supply constraints. Therefore, the selection cannot rely solely on favorable nuclear characteristics, such as physical half-life, emission profile, and chemical properties, or on biological factors like radiobiological efficacy. Consequently, the field has largely narrowed its focus to three alpha emitters with more feasible production pathways: astatine-211, actinium-225, and lead-212 [3,12].

Lead-212 is a particularly promising candidate for TAT as previously also discussed in a review by Scaffidi-Muta and Abell [13]. Due to its unique decay profile, lead-212 functions both as a beta emitter and as an *in vivo* generator of the alpha-emitting daughter nuclide bismuth-212, effectively delivering cytotoxic alpha radiation at the tumor site. Its relatively short physical half-life offers favorable irradiation characteristics, potentially reducing off-target radiation exposure when combined with a suitable vector molecule and improving therapeutic index compared to longer-lived alpha emitters [3]. An additional advantage of lead-212 is the availability of its chemically identical isotope, lead-203, a gamma emitter suitable for SPECT imaging. While its usefulness in the everyday clinical setting might yet need to be established as more convenient PET alternatives exist, having a radioisotope that can be imaged and quantified during clinical trials and research and development remains an advantage above most other therapeutic radionuclides.

In this review, we provide a comprehensive overview of the potential of lead-212 for TAT, covering the full translational pipeline from isotope production to clinical application. We begin by discussing the physical and chemical properties of lead-212 and its imaging counterpart, lead-203, emphasizing their compatibility for theranostic use. This includes a detailed examination of available production methods, with a focus on generator-based systems and the feasibility of large-scale supply. We then explore radiolabeling strategies and the coordination chemistry of lead isotopes, including a review of bifunctional chelators suited for stable complexation. Key considerations in designing lead-based radiopharmaceuticals are addressed, followed by a summary of current preclinical and early clinical studies, including data on

biodistribution, dosimetry, therapeutic efficacy, and toxicity. Finally, we outline the challenges and future directions for integrating lead-212 into routine clinical practice, highlighting its promise as a scalable and effective alpha-emitting therapeutic in nuclear medicine.

Radionuclide Properties and Production Methods of Lead-212 and Lead-203

Decay properties

Lead-212

Figure 1 displays the full decay scheme of lead-212, which is part of the decay chain of the long-lived radionuclides uranium-232 ($t_{1/2}$ = 68.9 years) and thorium-232 ($t_{1/2}$ = 1.04 x10^{10} years) [1]. With a physical half-life of 10.64 hours, lead-212 decays 100% through β- emission ($E_{β-}$ = 0.57 MeV) to bismuth-212 ($t_{1/2}$ = 60.5 min). Using lead-212 as an *in vivo* generator over the direct administration of bismuth-212 is hypothesized to have significant clinical advantages. Most notably, the longer half-life can lead to a ten-fold reduction in activity per patient administration compared to bismuth-212 alone [12].

The daughter radionuclide bismuth-212 decays via two paths, both resulting in an emission of one high-energy cytotoxic alpha particle. One decay path of bismuth-212 is through direct alpha particle emission for 35.93% to thallium-208 ($t_{1/2}$ = 3.06 min) with the residual 64.07% of bismuth-212 decaying to polonium-212 ($t_{1/2}$ = 0.3 μs) via another β- emission ($E_{β-}$ = 1.8 MeV). Polonium-212 is a pure alpha emitter and decays to stable lead-208. Lastly, thallium-208 decays via both beta particle and gamma emission to stable lead-208 [1,3,14].

During the decay of lead-212, both X- and gamma rays are emitted, allowing for convenient radioactivity quantification [15]. The principal gamma-line used for measurement of lead-212 is 238.6 keV (43.6%) while several lower energy X-rays such as 74.8 keV (0.28%), 77.1 keV (17.1%), 86.8 keV (2.07%), 87.3 keV (3.97%) and 89.8 keV (1.46%) can also be exploited for gamma-spectrometry using sodium iodide (NaI) detectors [16]. However, the daughter radionuclides bismuth-212 and thallium-208 emit additional X- and gamma-radiation during their decay. Therefore, to minimize interference from these progenies, it can be advantageous to restrict the measurement to a defined energy window (e.g. 60-110 keV) when using NaI detectors [16,17].

As is the case with other alpha-emitting radionuclides where unlabeled daughters must decay before quality control samples (TLC and HPLC) can be measured. In such cases, the true radiochemical

purity of a 212Pb-radiopharmaceutical is viewed as the relationship between free lead-212 and the 212Pb-radiopharmaceutical, with no influence by the non-bound bismuth-212 that was present in the reaction mixture. For both TLC measurements and fractions collected from radio-HPLC, it is important to wait 3-4 hours for the final determination of radiochemical purity [18]. Additionally, if concerns arise regarding the biodistribution of unbound bismuth-212 to the kidneys, DTPA in a concentration of 0.1 mg/mL can be added to provide renal protection.

When quantifying lead-212 using ionization chambers (dose calibrators), caution should be taken when using purified or freshly produced lead-212. Such lead-212 samples are devoid of daughters and subsequent ingrowth leads to time-dependent variability in the detected activity. Accurate measurements therefore require either the application of a correction factor or allowing sufficient time for equilibrium to be established (approx. six hours). Notably, predefined calibration factors or dial settings provided by the manufacturers are generally estimated for isolated lead-212, without accounting for daughter radionuclides. Since ingrown daughters such as bismuth-212 and thallium-208 contribute substantially to the dose calibrators' response, standardization or calibration of the measurement practices should be performed before studies are initiated [17]. International efforts are currently trying to standardize activity measurements of lead-212 through the implementation of appropriate calibration protocols.

Several studies have also explored the use of SPECT/CT for lead-212 and proposed some acquisition protocols that could be useful for image quantification [19–21]. It must be mentioned that lead-212 releases a high-energy gamma ray (2.6 MeV) during decay originating from its daughter radionuclide thallium-208. This necessitates the implementation of additional safety measures for healthcare personnel and researchers working with this radionuclide [1,3].

The preparation of sources containing lead-203 or lead-212 for the calibration or verification of medical imaging equipment can require large amounts of fluids. Plastic phantoms that are used for these devices, such as uniform cylinders, require liquids in which the radioactive substance is expected to be uniformly dissolved. The chemical form in which the radioactivity is present will be crucial for the calibration or verification steps. Therefore, the radiochemical form must be considered, and care must be taken such that the diluted substance remains uniform and does not adhere or precipitates to the

walls of the recipient or phantom during the entire procedure.

Lead-203

Lead-203 has a half-life of 51.9 hours and decays to stable thallium-203 via electron capture (EC), resulting in the release of a gamma photon (279 keV, Iγ=81%) compatible with SPECT imaging (Figure 2). This low-energy gamma photon, in addition to the residual 401 keV (5%) and 680 keV (0.9%) gamma energies, permits imaging using both a low and high energy SPECT collimator [4,23–26]. Due to the relatively long half-life of lead-203, extended imaging

is feasible to gather all necessary information needed for lead-212 treatment dosimetry [4]. The theranostic pairing of lead-203 and lead-212 is compelling due to their identical chemical characteristics, which warrants consistent biodistribution profiles [27]. However, it must be noted that lead-203 does not match the decay scheme (and changes in chemistry) of lead-212. Imaging using lead-203 can therefore not capture the daughter radionuclide decays (such as bismuth-212, which is the actual alpha emitter) which will have completely different biodistribution profiles if chelator dissociation occurs *in vivo*.


Figure 1: The decay chain of thorium-232 and uranium-232 as the source for lead-212, drawn with a licensed version of BioRender.com [22].

Figure 2: the decay scheme of lead-203, drawn with a licensed version of BioRender.com [28].

Current strategies for production

Lead-212

The production of lead-212 is based on generator systems separating lead-212 from decaying parent radionuclides thorium-228 or radium-224. Lead-212 generators reported in literature describe the separation of daughter radionuclides through either a cation exchange column loaded with thorium-228 (Figure 3A) or radium-224 (Figure 3B) or emanation of the gaseous daughter radionuclide, radon-220 (Figure 3C and 3D) [4]. Many generators have been described, and some technical details are provided in Table 1.

Column generator systems based on thorium-228

The use of thorium-228-based lead-212 generators may hold some benefits such as a long half-life of 1.9 years limiting the generator replacement, reducing production cost, and lowering radiation dose to exposed personnel. A complex system was described early by Morimoto and Khan [30] through the electrodeposition and adsorption of ^{228}Th-hydroxide on a positive aluminum plate. The lead-212 is moved through a potential difference to a negatively charged platinum coil, which is then dissolved after deposition. However, this method yielded very low yields of approximately 20%.


Figure 3: A and B) column generators based on respectively thorium 228 and radium-224 [4,29], and C and D) examples of radon-220 gas emanation generators. Drawn with a licensed version of BioRender.com [2,28].

Table 1: A summary of the characteristics of reported lead-212 generators (grouped by parent and arranged chronologically):

Parent radionuclide	Matrix	Eluant	Manipulation of eluate	Yield	Ref
Column generator systems based on thorium-228					
Thorium-228 (37 MBq)	Na$_2$TiO$_3$ resin D-50 resin	Elute resin 1 with H$_2$O, resin 2 with 2 M HCl	No manipulation is described	85% maximum yield	[31]
Thorium-228, loaded in 4 M HNO$_3$	UTEVA resin SR resin prefilter resin	^{212}Pb recovered from Sr resin with 10 mL 6 – 12 M HCl	No manipulation is described	>95%	[32]
Thorium-228, loaded in 40 mL of 1 M HNO$_3$ stock solution	Pb resin column	1 mL of 1 M NH$_4$OAc	No manipulation of the eluate is required	69.3 ± 4% yield	[4]
Thorium-228, loaded in 2 M HNO$_3$ solution (22.9 MBq)	Pb resin Dowex 1 x 8 resin	Elute resin 1 with 2 M HCl and resin 2 with 0.01 M HCl	pH adjusted with NH$_4$OAc	First elution 89% recovery; second elution 97% recovery	[23]
Column generator systems based on radium-224					
Radium-224, up to 925 MBq	AG-MP50 cationic exchange resin	2 M HI	The acid is neutralized with 1 M sodium acetate for further chemistry	90% yield	[35]
Radium-224	Cationic exchange resin Dowex-50X8-100 resin Dowex-1X-200 resin	3 mL of 2 M HCl	The eluate was left in a fume hood for radon-220 to dissipate and passed through an additional column to remove radium-224 breakthrough	Not provided	[40]
Radium-224, 0.15 MBq	Dowex 50W-x8 column	1 M HCl	No manipulation is described	Reported as quantitative	[36]
Radium-224		2 M HCl	Evaporation, then 3 digestions with 8 M HNO$_3$, reconstitution with HNO$_3$ 0.1 M and neutralization with 5 M NH$_4$OAc	Not provided	[14]
Radium-224, up to 740 MBq loaded	AG-MP50 cationic exchange resin	4 mL of 2 M HCl	Evaporation of eluant, 3 repeat digestions with 8 M HNO$_3$, extraction with 0.1 M HNO$_3$, and neutralization with 5 M NH$_4$OAc	>90%	[28]
Radium-224	AG-MP50 resin, Pb resin	Resin 1 eluted with 2 M HCl followed by resin 2 eluted with 5 M NH$_4$OAc	No further manipulation is needed	86% yield from column 1 and 75.4% yield from column 2 (46.6 MBq/ml)	[47]
Emanation generators based on capturing gaseous radon-220 [from either thorium-228 or radium-224					
Thorium-228 (20-30 MBq)	Radon-220 gas collected in removable polyethylene bottle	Water (70% efficiency), 1 M NaCl (99% efficiency)	No manipulation is described	50 to 11% based on the age of the generator (tested to 1 year)	[44]
Thorium-228, up to 45 GBq	Radon-220 gas collected into a glass bubbler	HNO$_3$ solution	No manipulation is described	70% yield (up to 25 GBq per day)	[33]
Thorium-228 (7.05 MBq)	^{228}Th on Dowex ion exchange resin. Radon-220 gas is collected in a helix shaped vessel.	0.1 M HCl	No manipulation is described	40% collection efficiency from Dowex resin.	[45]
Radium-224 or thorium-228	Quartz wool containing parent, glass (Duran) flask to catch radon-220	Flask washed with 0.5 – 1 mL 0.1 M HCl	pH adjusted with NH$_4$OAc or sodium acetate	Glass collector trapped 62 – 68% lead-212, eluted with >87% efficiency.	[2]
Radium-224	Duran-flask-method (CERN generator)	Flask rinsed 1-4x 1mL 0.1M HCl	Pb resin, eluted with NaAc/AcOH and purification after radiolabeling C18 column	Maximum recovery rate 31.6 ± 2.7%	[46]
Radium-224	VMT-α-GEN (PerspectiveTx) Non-FDA-approved	Elution with 4 mL 2 M HCl and 1 mL H$_2$O	Pb resin, eluted with NaAc/AcOH and purification after radiolabeling on C18 column	Maximum recovery rate 76 ± 9%	[48]

A first ^{228}Th/^{212}Pb column generator was introduced by Zucchini and Friedman in 1982, consisting of a novel two-step system based on the cation exchange principle. In the first column, both thorium-228 and radium-224 are absorbed on Na$_2$TiO$_3$. Radon-220 is eluted before loading onto a second column containing D-50 cation exchange resin, and from this second column, lead-212 could be eluted using 2M HCl with a maximal yield of 85%. However, small amounts of thorium-228 and radium-224 breakthrough were noted [31]. In a more advanced system, McAlister and Horwitz described a lead-212-generator from thorium-228 as parent radionuclide, using a three-cartridge system of UTEVA resin (retaining thorium-228), Sr resin (capturing lead-212), and a prefilter resin to remove

extractant traces. Radium-224 is not retained by this system. Afterwards, lead-212 is recovered with a high yield of > 95% [32].

Column generator systems based on Radium-224

Upscaling of thorium-228 based generators to produce clinical amounts of activity is found problematic due to radiolytic damage to the columns [33,34]. To circumvent this problem, ^{224}Ra-based column generators are being investigated. These generators have a much shorter shelf life due to the parent half-life of 3.6 days. A crucial step is the complete separation of radium-224 from thorium-228. Atcher *et al*. described the use of anion exchange columns early on [35]. The pure radium-224 can then be loaded on a cartridge system (for example, a cation

exchange resin) to create a generator from which lead-212 can be eluted using an acidic medium [28,35–39]. It is important to note that this generator system has been in use now for more than 30 years and is supplied by OranoMed and Oak Ridge National Laboratory [34]. However, the use of additional purification columns has been suggested to remove all traces of the radium-224 from the lead-212 eluate and ensure no breakthrough [40,41].

Emanation generators based on capturing gaseous radon-220

The principle of radon-220 emanation for use in lead-212 production was described early on by Gregory *et al.* [42] using the parent radionuclide thorium-228. In such systems, radon-220 is trapped in a secondary chamber after emanation from either the parent radionuclide thorium-228 or radium-224. Lead-212 is subsequently collected after radon-220 decay. Similarly, a $^{228}Th/^{212}Pb$-generator system based on this principle was patented by Norman *et al.* in 1991, where decayed radon-220 gas from thorium-228 placed in one chamber is diffused to a second chamber, after which lead-212 may be collected [43].

Hassfjell and Hoff reported a $^{228}Th/^{212}Pb$-generator using a different collection principle in 1994, where a [^{228}Th]barium stearate source was placed in an air-tight collection chamber to increase the diffusion distance of radon-220 gas. Following the deposition of lead-212 on the collection chamber walls, this could be collected using distilled water [44]. Later, this generator was adapted to produce increased levels of radioactivity, closer to clinically relevant amounts, by collecting radon-220 emanating from [^{228}Th]barium stearate in a glass bubbler filled with an organic solvent at -72 °C [33].

Boldyrev and co-workers introduced a helix-shaped collector vessel into their $^{228}Th/^{212}Pb$-generator, in which emanating radon-220 is transported and the deposited lead-212 may be collected using 0.1M HCl [45]. Li and co-workers [2] recently proposed a $^{224}Ra/^{212}Pb$-generator based on this radon-220 emanation principle, similar to previous $^{228}Th/^{212}Pb$-generator systems. However, the scalability of this system is lacking due to the use of a single chamber generator consisting of an inverted 100 mL glass flask containing radium-224 in the screw cap, pipetted onto quartz wool. After decay, lead-212 may be extracted from the interior of the glass flask [2]. Recently, CERN developed a similar generator system, leveraging its high yields in extracting radium-224 from irradiated thorium-232 targets at the MEDICIS facility [46]. Regular supply is now available, either directly from the MEDICIS facility or via the PRISMAP infrastructure [12].

Column generator systems vs emanation-based systems

Two main strategies for lead-212 based generators exist namely immobilizing the long-lived parent on a solid support that allows periodic elution, and emanation-based generators where radon-220 is collected in a vessel or chamber, after which lead-212 is collected subsequently by elution. Both options have advantages and disadvantages. In the column-based approach, the parent is fixed to the matrix and allows for a more robust and repeatable elution and minimal handling of parent radionuclides. Chromatographic column generators are more optimal for upscaling radiopharmaceutical production and easier to incorporate in automated production strategies. It is important to determine whether there could be radiolytic damage of the columns if thorium-228 is kept stored absorbed onto it as this can influence column efficiency and yield. On the other hand, emanation design physically separates the daughter radionuclides from the parent radionuclides, providing a very pure lead-212. This comes at the cost of lower yields and greater complexity in generator handling.

Alternative Lead-212 Sources and Radiochemical Processing

A system exploring the use of the parent radionuclide uranium-232 (deposited on a steel plate) was investigated in the past but was found unsuitable for medical purposes [49]. Bartoś and co-workers also described the separation of lead-212 (1 MBq) from uranium-232 but did not present or evaluate their method as a generator system. Uranium-232 and decay daughters were loaded on an HDEHP-Teflon column, subsequently radium-224 was eluted by 0.1 M HNO_3 and loaded on a cation exchange resin (Dowex 50 x 8). Lead-212 was then eluted with 0.1 M HCl for further processing [37].

Most generator systems yield large volumes of eluted lead-212, often in solvents incompatible for radiochemistry procedures. Therefore, additional evaporation may be required, increasing the chance of impurities and reducing the production yield [3]. Currently, two systems, using respectively a thorium-228 and radium-224 based column generator, describe the final elution in an NH_4OAc solution, which is directly compatible with radiolabeling [4,47]. Another technology additionally added an anion exchange purification column to reduce metal impurities, such as Fe^{3+}, without significant loss of lead-212 activity [23].

Availability and Supply of Lead-212

The development of lead-212 generator systems represents a dynamic and rapidly advancing field,

driven by significant industrial and academic investment. Optimization of both column-based and emanation-type generators has demonstrated the feasibility of scaling-up the production to meet clinical demand. Moreover, both centralized and decentralized production of lead-212 is actively being pursued within the radiopharmaceutical industry, underscoring the versatility and potential of lead-212 supply strategies.

As for access to thorium-228 or radium-226, it is stated in a recent commentary by Zimmermann [3], that there are ample sources from legacy nuclear material that yield thorium-228. Thorium-228 as starting material can be produced by several methods. This includes the use of radium-226 as target material, spallation of thorium-232 or the isolation of thorium-228 from legacy stockpiles. For an in-depth discussion on the production methods of thorium-228 we refer the reader to previously published reviews [1,12,13]. Since radium-226 is the main starting material to produce radium-223 and actinium-225, direct production of lead-212 is also deemed feasible from radium-226 via the $^{226}Ra(\gamma,2n)^{224}Ra$ reaction using a linear accelerator. Therefore, no shortage of lead-212 is expected.

In Figure 4, the recently published distribution of sites that have experience in the production of lead-212 is presented [12]. Lead-212 is also available from suppliers (such as OranoMed) [50] in the form of $^{212}Pb(HNO_3)_2$ as an eluate. Its half-life of 10.6 hours allows for distribution to other radiopharmaceutical sites [50,51].

Lead-203

Lead-203 cyclotron production

The cyclotron-based production of lead-203 can be achieved through charged particle bombardment of natural thallium consisting of 29.5% thallium-203 and 70.5% thallium-205 or isotopically enriched thallium [24–26]. Theoretically, lead-203 could also be produced through bombardment of enriched mercury, but this is considered too expensive [24]. A low energy proton beam (e.g., 13 MeV) results in the production of lead-203 from the $^{203}Tl(p,n)^{203}Pb$ nuclear reaction using isotopically enriched thallium-203 [52]. Production yield is limited due to the low cross-section of this reaction at 11 MeV (111 mb) or 13 MeV (37.4 mb) and the low melting point of thallium (304 °C). This results in low thermal stability [25,26]. Using this production technique, the use natural thallium is avoided due to its high fraction of thallium-205 which will result in the production of lead-205 ($T_{1/2}$ 15.3 My) following the $^{205}Tl(p,n)^{205}Pb$ reaction, complicating the production process.


Figure 4: Geographical spread of sites that currently have experience in the production of lead-212 (reprinted with permission, [12]).

Alternatively, lead-203 may be produced using a proton energy beam above 17 MeV (e.g., 24 MeV) through the ^{205}Tl(p, 3n)^{203}Pb nuclear reaction, which is ideally performed using isotopically enriched thallium-205 to avoid the production of lead-201 from the ^{203}Tl(p, 3n)^{201}Pb nuclear reaction when using natural thallium [53]. In this reaction, a larger cross section was reached (σmax = 1193 mb at 28 MeV) using isotopically enriched thallium-205, resulting in a high yield of lead-203. When natural thallium is used as a target material, a suitable decay time of the ^{201}Pb ($t_{1/2}$ = 9.3 h) by-product is required before the purification of lead-203, since these radioisotopes cannot be separated efficiently [41].

The production of lead-203 is also possible through deuteron bombardment of isotopically enriched thallium-203 from the ^{203}Tl(d,2n)^{203}Pb nuclear reaction. However, isotopically enriched thallium-203 is more expensive than thallium-205 due to its abundance in naturally occurring thallium [26]. The use of sealed solid target material, as described by Nelson *et al.*, further improves production yield by enabling target material cooling and preventing thallium oxidation [25]. Moreover, since enriched target materials are expensive, production methods aim to recycle the thallium to decrease production costs. This can be done through multiple methods such as chemical oxidation and precipitation as described by McNeil *et al.* [23].

Logically, purification of lead-203 is similar to lead-212 purification methods developed and normally includes the application of anion exchange or Pb-selective resins. Again, these purification steps may result in large volumes of eluate requiring evaporation of the lead-203 eluates and re-dissolution before radiolabeling. Saini *et al.* described a robust purification method to produce high-purity lead-203 using a two-column separation method. The irradiated targets are first dissolved in HNO_3 and loaded onto a Pb-selective resin. Residual thallium is removed from the resin bed by washing it with additional HNO_3 before lead-203 is eluted as an NH_4OAc solution. This eluate was then loaded onto a second cation exchange resin for concentration, from which lead-203 was eluted as [^{203}Pb]PbCl$_2$ using HCl. This allows for direct radiolabeling without evaporation [54]. A summary of the production methods of lead-203 is provided in Figure 5.

Availability and Supply of Lead-203

The availability of lead-203 is limited to the available production facilities equipped with medium-energy cyclotrons and the access to enriched target material [3]. However, growing interest in lead-203 as a diagnostic counterpart to lead-212 in theranostic applications has prompted increased efforts to improve supply chains and expand availability through both academic and industrial initiatives.

In Figure 6, we provide a lead-203 production atlas, to highlight locations where lead-203 was obtained from in the past five years, reported in literature or via an online search for suppliers. The terms "producer" and "supplier" should not be interpreted literally in this context. This might not be an exhaustive list of sites that have experience in the production of lead-203 or are able to provide lead-203 for preclinical and/or clinical purposes.

Chemical characteristics of lead

In aqueous solution at ambient conditions, lead exists predominantly as a divalent cation (Pb^{2+}) with an ionic radius of 1.19 Å (coordination number of 4-12) [34,59,60]. As a borderline cation, Pb^{2+} can interact with both hard donors (e.g., oxygen) and soft donors (e.g., sulfur) [60,61]. This allows Pb^{2+} to form complexes with a wide range of stabilities and geometries.

Although the ionic radius of Pb^{2+} is similar to that of Sr^{2+} (1.18 Å), its coordination behavior is notably distinct due to relativistic effects. As a heavy element, lead experiences relativistic contraction of its 6s orbital, lowering its energy and reducing its participation in bonding, an effect known as the inert pair effect. This phenomenon contributes to the formation of asymmetric or hemidirected coordination complexes.

In contrast, Sr^{2+} lacks this inert pair effect and typically forms more rigid, symmetric complexes with a strong preference for hard donors like oxygen. Pb^{2+}, on the other hand, exhibits greater flexibility in chelation due to its ability to coordinate with both hard and soft donors. This unique stereochemical behavior underlies the distinctive chelator preferences of Pb^{2+} and sets it apart from other divalent cations of similar size [34,59,62–65]. The lone pair may either be stereochemically active, contributing to an asymmetric coordination environment (hemidirected geometry), or stereochemically inactive, resulting in a more symmetrical arrangement of ligands (holodirected geometry).

When the lone pair is active, it occupies one side of the coordination sphere, forcing ligands to arrange themselves on the opposite side, creating an asymmetrical (hemidirected) complex. In contrast, when the lone pair is inactive, ligands are distributed more evenly around the Pb^{2+} center, yielding a symmetrical (holodirected) complex. The stereochemical activity of the lone pair is strongly influenced by the nature and coordination number of

the ligands. Complexes with low coordination numbers (< 6) tend to exhibit lone pair activity and hemidirected geometries, while high coordination numbers (> 8) often suppress lone pair influence, leading to holodirected, more symmetrical structures [66–69]. Larger ligands or those that promote higher coordination numbers generally reduce lone pair activity, contributing to increased stability and symmetry. The industry standard chelator TCMC does achieve superior complex symmetry and kinetic inertness *in vivo*, by having a high coordination number of 8 which provides, by being bulky and flexible, enough donor atoms to achieve quasi-holodirected coordination geometry. By achieving this, the lone pair no longer dictates geometry or influences stability *in vivo* [66].

However, this is a general trend, and both steric hindrance and the electronic properties of the ligands also play a critical role in modulating the lone pair behavior of Pb^{2+}, including in lead-212 complexes [34,64,65,70,71].

Bifunctional Chelating Ligands for Lead and Practical Considerations

Bifunctional chelators play a pivotal role in the development of novel radiopharmaceuticals, particularly those involving radiometals [13]. They are designed with two distinct functional domains: the first forms a stable coordination complex with the radiometal, ensuring *in vivo* stability by preventing transchelation or transmetalation; the second enables covalent attachment to a vector molecule. Common strategies for this linkage include the formation of amide or thiourea bonds, with amide bonds generally offering superior stability, including enhanced resistance to radiolysis. The ideal bifunctional chelator-radionuclide complex should be both thermodynamically stable and kinetically inert, and the complexation should take place under mild radiolabeling conditions if needed for heat sensitive

Figure 5: A) A summary of possible lead-203 production routes [24,53] B) An example of a separation scheme for purification of lead-203 from a thallium target, drawn with a licensed version of BioRender.com [54].

vectors. The choice of chelator is therefore critical, as it affects not only radiolabeling efficiency, but also the pharmacokinetics, biodistribution and safety profile of the final radiopharmaceutical.

Small acyclic ligands such as EDTA and acetylacetonate (ACAC) have proven suboptimal for chelating lead radioisotopes, as they leave coordination sites exposed and do not form sufficiently stable complexes. In contrast, larger macrocyclic ligands like DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid; Figure 7A) and TCMC (also known as DOTAM, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra(2-carba moylmethyl); Figure 7B) offer improved steric and electronic environments for stable coordination [34]. However, the stereochemical behavior of Pb^{2+} within these chelates, specifically whether the $6s^2$ lone pair is holodirected or hemidirected, remains a topic of debate [4,34,72,73].

The combination of a lower coordination number and the asymmetry resulting from the active lone pair often results in weaker bonds and lower stability of the complex. Highly symmetrical complexes with distributed ligand bonds reduce steric strain (crowding of atoms) and this maximizes the strength of the metal-ligand interactions [34]. Symmetry also minimizes repulsion between bonded and non-bonded electrons, making the complex thermodynamically more favorable [34,73]. In addition to electronic and steric factors, chelation enhances stability by reducing entropy loss upon complex formation. Macrocyclic ligands like DOTA and TCMC pre-organize donor atoms, which leads to improvement of the binding affinity of Pb^{2+} [73].

In addition, to address the unique coordination chemistry of lead, a lead-specific chelator (PSC) has also been developed, designed to optimize complexation specifically for lead radioisotopes [55].

DOTA and TCMC

Chelators that incorporate hard donor atoms, such as the oxygen atoms in DOTA, contribute significantly to complex stability through strong metal-ligand interactions [34]. However, soft donor atoms, typically offer even greater binding affinity for soft (Lewis) acids like Pb^{2+}, especially in low-coordination environments where lone pair effects are more pronounced [74,75].

In practice, when compared to DOTA, the nitrogen groups in TCMC provide softer donor capacity and are more favorable for a borderline acid like Pb^{2+} The soft-soft interactions between Pb^{2+} and the TCMC ligand are stronger and more stable than that of the hard-soft interactions between Pb^{2+} and oxygen present in DOTA [55,73,74].


Figure 6: Geographical spread of sites that currently have experience in the production of lead-203 [23,54–58].

Figure 7: The chemical structures of A) DOTA B) TCMC or DOTAM C) PSC.

High coordination ligands, such as TCMC, mitigate lone pair effects and ensure symmetrical complexation, leading to greater overall stability [34]. Although DOTA provides a rigid macrocyclic framework, its coordination with Pb^{2+} does not fully suppress lone pair activity, whereas TCMC achieves higher symmetry and stability (empirically proven) with less effect of the lone pair on geometry [73,74,76].

PSC

The PSC chelator (1,4,7,10-tetraazacyclodo-decane-1,4,10-triacetic acid, 7-(2-carbamoylmethyl)), incorporates a strategic mix of amide and carboxylic acid donor groups. This balance enables PSC to match the electronic preferences of Pb^{2+}, optimizing both affinity and kinetic stability [55]. In addition, PSC demonstrates a zero formal charge when coupled to lead, which is in contrast with [Pb]DOTA and [Pb]TCMC, demonstrating a net formal charge of -2 in the case of DOTA in its fully deprotonated form, and +2 in the case of TCMC [55]. It is postulated that this neutral charge might lead to additional stability and retainment of the bismuth-212 daughter using the PSC chelator [55]. Ligands with nitrogen donors enhance lone pair activity through covalent interactions, reducing the stability of the complex, but if combined with oxygen-pendent arms (e.g., PSC), this can be balanced out. Interestingly a recent study by Saidi and co-workers [77] demonstrated that between DOTAM, PSC or DOTA, DOTAM still demonstrated superior chelation efficacy and faster kinetics paired with less kidney accumulation. We expect more information on the ideal chelation strategy for lead-212 to become available.

Other chelators

Novel chelator development for lead-212 is an active field, and more stable complexes have been reported. For example, Tosato *et al.* report the exploration of several macrocyclic ligands of which DO2A2S and DO3SAm, both DOTA derivatives with varying pendant arm softness, demonstrated the highest complexation efficiency. Additionally, chelators with different macrocyclic backbones, TACD3S, TRI4S, and TE4S were explored but showed no superiority [78]. Macropa, a macrocyclic chelator with two pendant picolinic side arms, was studied for radiolabeling of lead-212 by Blei *et al.* [61, 79]. The acyclic DTPAm chelator showed promise for chelating lead-203 in one study although no measurement of kinetic stability was reported [80]. It was not our aim to provide an exhaustive review of all the novel chelators that are currently under investigation, but we refer the reader to the recent review by Scaffidi-Muta and Abdell for a discussion (including structures) of standard chelators, acyclic chelators, cyclen macrocycles and alternative macrocycles that have been applied for chelation of lead isotopes [13].

Recoil and Coordination Chemistry Challenges

A persistent challenge in the development of lead-212-based radiopharmaceuticals is the potential decoupling of the daughter nuclide bismuth-212 from the chelator during decay. This can occur due to two key mechanisms: (1) the physical recoil energy released during beta decay, which may disrupt the radiometal-chelate complex, and (2) subtle changes in coordination chemistry between the parent lead-212 and the daughter bismuth-212, leading to reduced binding affinity. It is however commonly accepted that the recoil energy (mechanism 1) is insufficient to break metal ligand bonds, and that the reorganization of valence electrons (mechanism 2) is mostly to blame for the release of the bismuth daughter upon decay [29]. Upon beta-minus decay, Pb^{2+} becomes Bi^{3+}, and bismuth has a smaller ionic radius compared to lead and is a harder Lewis acid which prefers oxygen donors.

In contrast to some other alpha emitters, the choice of chelator seems to have at least some mild influence on the stable chelation of lead-212 and progenies [81]. Specifically, the recoil effect following the beta-minus decay of lead-212, with typical recoil

energies in the order of a few eV, is much less pronounced than that observed in alpha emitters such as actinium-225, where alpha decay recoil energies can exceed 100 keV [82].

For example, a study investigating the chemical transformation of [212Pb]Pb-DOTA to [212Bi]Bi-DOTA reported that approximately 36 ± 2% of the resulting bismuth-212 was unchelated [29]. This issue is of particular concern due to the known renal accumulation and toxicity associated with free bismuth-212. Supporting this, [203Pb]Pb-DOTA-biotin was found to be stable for up to four days, whereas [212Pb]Pb-DOTA-biotin showed over 30% release of bismuth-212 after just four hours [83]. Although the data are unpublished, Maaland *et al.* reported that the use of TCMC as a chelator reduced bismuth-212 release to approximately 16% [84], suggesting an improvement in daughter retention. Conflicting results were presented by Westrøm and co-workers suggesting the value to be closer to 30%, similar to that reported for [Pb]DOTA [14]. If chelator decoupling happens *in vivo*, this effect will not be depicted by lead-203 based imaging, as this radioisotope does not have bismuth-212 in its decay scheme.

Despite ongoing research into alternative chelators, TCMC remains one of the most widely used bifunctional chelators for lead-based radiopharmaceuticals. Its strong coordination with Pb2+ ions, excellent *in vivo* stability, and commercial availability make it a reliable choice for both clinical and investigational use. Clinically relevant examples include [212Pb]Pb-TCMC-trastuzumab for HER2-positive cancers and [212Pb]Pb-DOTAM-TATE, targeting somatostatin receptors in neuroendocrine tumors. TCMC's established safety profile and performance continue to underpin its dominance in the field of lead-based TAT.

Preclinical and Clinical Proof-of-concept Studies with Lead-based Radiopharmaceuticals

Given the limited understanding of the stability, radiobiology, and therapeutic efficacy of 212Pb-based radiopharmaceuticals, ongoing research is essential to assess their feasibility for clinical application. A summary of currently investigated targets and radiopharmaceuticals (both preclinical and clinical) is summarized in Figure 8. Drawn with a licensed version of BioRender.com.


Figure 8: Potential targets investigated in preclinical and clinical studies using lead-212 or lead-203 based radiopharmaceuticals. Classified based on type of vector molecule and target. Constructs being evaluated in clinical trials are underscored. PSMA: prostate-specific membrane antigen; FAP: fibroblast activating protein; CXCR4: C-X-C motif chemokine receptor 4; SSTR: somatostatin receptor; MC1R: melanocortin-1 receptor; GRPR: gastrin-releasing peptide receptor; BB2r: bombesin subtype 2 receptor; HER2/1: human epidermal growth factor receptor 2/1; EGFR: epidermal growth factor receptor; VCAM: vascular cell adhesion molecule; PTK-7: protein tyrosine kinase 7; MP: microparticles.

The choice of vector molecule paired with lead radioisotopes has profound impact on the biological behavior of the radiolabeled compound. Given the relatively short half-life of lead-212, small molecules and peptides provide the best matched pharmacokinetic profile with a similar biological half-life [53]. They have the advantage of a rapid tissue penetration, distribution and relatively fast clearance from the systemic circulation [85].

In contrast, full-length antibodies have more limited tumor penetration and a prolonged systemic circulation, which is not ideal given the half-life of lead-212. However, antibodies are still among the most widely investigated vectors in TAT due to their high target specificity [85]. Moreover, this mismatch in biological and radiopharmaceutical half-lives can be mitigated in certain cases by compartmental administration routes, such as intraperitoneal (i.p.) injection, particularly for targeting disseminated peritoneal disease [86]. Antibody fragments offer a promising alternative, retaining target specificity while exhibiting improved tumor penetration and faster clearance, making them more compatible with the pharmacokinetics of lead-212 [87].

Lastly, nanotechnology such as microparticles have also been explored for lead-212-based TAT. These systems can be engineered for multivalent targeting and enhanced tumor retention but pose additional challenges related to biodistribution and clearance [88]. This review provides an overview on all lead-212-based constructs evaluated in preclinical models, categorized by their vector type and target, with reference to their lead-203 theranostic counterpart where applicable. Moreover, a list of clinical trials registered on clinicaltrials.gov (accessed 2025/09/01) is provided in Table 2.

Small molecule and peptidomimetic-based radiopharmaceuticals

Prostate-specific membrane antigen (PSMA)

PSMA-targeted small molecules have been widely applied clinically for RNT, especially labeled with lutetium-177 but also alpha emitters like actinium-225 [89]. While PSMA is limitedly expressed in healthy tissues, a majority of prostate cancer metastases are found to overexpress PSMA, making PSMA an ideal target for TRT [90].

Preclinical research

Compared to the reference DOTA conjugated [^{212}Pb]Pb-PSMA-617 construct, [^{212}Pb]Pb-NG001, a TCMC-conjugated PSMA ligand, demonstrated comparable tumor uptake and reduced kidney retention when evaluated in C4-2 (PSMA-expressing prostate cancer cell line) bearing mice [90,91]. In a follow-up study, [^{212}Pb]Pb-NG001 treatment demonstrated an activity-dependent delay in tumor growth and prolonged survival in human prostate cancer (PC-3 PIP) bearing mice. Fractionated administration seemed to enhance this beneficial result [92]. Many ^{212}Pb-labeled PSMA ligands have been described in the literature. A series of low-molecular-weight PSMA ligands (L1-L5) were developed based on the 4-bromobenzyl derivative of lysine-urea-glutamate and subsequently evaluated preclinically after radiolabeling with both lead-203 and lead-212 (Figure 9). All the TCMC-based agents demonstrated lower renal retention compared to DOTA-based variants. A subsequent *in vivo* therapy study showed [^{212}Pb]Pb-L2 delayed tumor growth successfully in PSMA-positive PC3 PIP xenografts and micro-metastatic models [93]. Dos Santos *et al.* introduced another PSMA ligand for lead-203/ lead-212 theranostic use. [^{203}Pb]Pb-PSMA-CA012 presented with optimal uptake, and a first-in-human dosimetry study was subsequently performed using [^{203}Pb]Pb-PSMA-CA012 in two prostate cancer patients. However, this study only reported a theoretical extrapolation to [^{212}Pb]Pb-PSMA-CA012 without actual preclinical assessment [94].

Clinical research

Patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) after androgen receptor pathway inhibitors and chemotherapy are eligible for the EMA- and FDA-approved therapy [^{177}Lu]Lu-PSMA-617 (Pluvicto) [95]. However, up to 30% of these patients either fail to respond or develop resistance to this beta-RNT [96]. In such cases, PSMA ligands labeled with alpha emitters may provide improved therapeutic efficacy. An early phase 1 trial (NCT05725070) investigated the imaging potential of [^{212}Pb]Pb-NG001, a PSMA-targeted radioligand, in three patients with progressive mCRPC selected by [^{18}F]PSMA-1007 PET imaging. Each subject received a single intravenous (i.v.) micro-amount of [^{212}Pb]Pb-NG001 (9.4 ± 0.3 MBq). Planar and SPECT/CT gamma camera imaging was performed 1-3 hours and 16-24 hours after radioligand injection. Blood analyses confirmed the post-injection stability of the radioligand. Although gamma camera imaging was feasible, the low injected activity presented challenges. Nonetheless, [^{212}Pb]Pb-NG001 effectively targeted mCRPC, demonstrated a favorable biodistribution profile with potentially low uptake in the salivary glands, and was well-tolerated without adverse effects at these subtherapeutic micro-amounts [97].

Table 2: A summary of all clinical trials (active or completed) investigating lead isotope-based theranostics (clinicaltrial.gov - Sept 2025). Grouped by target and listed consecutively by trial start date.

Radioconjugate	Target	Patient population	Procedure	Source of Lead-212	Principle findings	Study identifier and dates
Small molecules						
[²¹²Pb]Pb-NG001	PSMA	Patients with progressive, PSMA-expressing mCRPC (n=3)	Phase 0 and 1: Gamma camera imaging was performed at 1-3h and 16-24h p.i. of 9.4 MBq conjugate	Artbio	Feasible gamma counting and favorable dosimetry	**NCT05725070** [2023]
[²¹²Pb]Pb-ADVC001	PSMA	Patients with PSMA-expressing mCRPC	Phase 1 and 2: Dose escalation and expansion study administering up to 200 MBq conjugate i.v. in 4-6 cycles, two/four weeks apart	Advancell – based on thorium-228	Not available	**NCT05720130** [2023-2029]
[²¹²Pb]Pb-Pentixather	CXCR4	Patients with CXCR4-expressing atypical lung carcinoids	Early Phase 1: Two treatment cycles, 6 weeks apart in combination with [²⁰³Pb]Pb-Pentixather SPECT imaging pre and post-therapy (3 months)	University of Iowa – lead-212 source not disclosed	Not yet available	**NCT05557708** [2024-2028]
[²¹²Pb]Pb-PSV359	FAP	Patients with FAP-expressing solid tumors	Phase 1 and 2: Dose escalation and expansion study with 92.5 - 370 MBq of iv administered radioconjugate	Perspective technology – based on radium-224	Not yet available	**NCT06710756** [2025-2032]
Peptide-based vector						
[²¹²Pb]Pb-DOTAM-TATE	SSTR	Patients with SSTR-expressing NETs (n=20)	Phase 1: Dose escalation (1.13 - 2.50 MBq/kg/cycle) of i.v. administrated conjugate	Oranomed – based on radium-224	Well-tolerated	**NCT03466216** [2018-2022]
		Patients with SSTR-expressing NETs (n=66)	Phase 2: IV. injection of 2.5 MBq/kg/cycle conjugate for 4 cycles	Oranomed – based on radium-224	Preliminary results: ORR of 47.2%	**NCT05153772** [2021 - 2026]
[²⁰³Pb]Pb-VMT01	MC1R	Patients with MC1R-expressing metastatic melanoma	Phase 1: SPECT/CT images were obtained at 1h, 4h, and 24h p.i. of 555 - 925 MBq conjugate	Perspective technology – based on radium-224	Dosimetry successfully performed on SPECT/CT scans	**NCT04904120** [2021-2022]
[²¹²Pb]Pb-DOTAM-GPR1	GRPR	Patients with recurrent or metastatic GRPR-expressing tumors	Phase 1: Dose escalation and expansion study with 3+3 design, dose increments of ±30%, four cycles eight weeks apart in MAD regimen	Oranomed – based on radium-224	Not yet available	**NCT05283330** [2022-2025]
[²⁰³Pb]Pb-VMT-α-NET	SSTR	Patients with SSTR-expressing NETs	Early Phase 1: SPECT/CT images were obtained at 1h, 4h, 24h, and 48h p.i. of 185 MBq conjugate	University of Iowa – lead-212 source not disclosed	Dosimetry performed on SPECT/CT scans enabled dose selection for cohort 1 of NCT0614836	**NCT05111509** [2022-2025]
[²¹²Pb]Pb-VMT-α-NET	SSTR	Patients with SSTR-expressing NETs	Early Phase 1: Dose escalation study with up to two i.v. injections of conjugate at least eight weeks apart, co-administered with reno-protective amino acids	University of Iowa – lead-212 source not disclosed	Not yet available	**NCT06148636** [2023-2027]
		Patients with SSTR-expressing NETs	Phase 1 and 2: Dose escalation with four treatment cycles, every eight weeks including reno-protective amino acids	Perspective technology – based on radium-224	Not yet available	**NCT05636618** [2023-2029]
		Patients with SSTR-expressing NETs	Phase 1: Dose escalation, 4 treatment cycles every eight weeks, dosimetry - 3 year follow-up	National Cancer Institute – lead-212 source not disclosed	Not yet available	**NCT06479811** [2025-2029]
		SSTR-expressing NETs, pheochromocytomas, or paragangliomas	Phase 1 and 2: Dose escalation, 4 treatment cycles every eight weeks in a re-treatment setting (previous PRRT)	National Cancer Institute – lead-212 source not disclosed	Not yet available	**NCT06427798** [2025-2039]
[²¹²Pb]Pb-VMT01	MC1R	Patients with MC1R-expressing metastatic melanoma	Phase 1 and 2: i.v. injection of 111-555 MBq conjugate in monotherapy or in combination with nivolumab	Perspective technology – based on radium-224	Not yet available	**NCT05655312** [2024-2029]
Antibody-based vector						
[²¹²Pb]Pb-TCMC-trastuzumab	HER2	Patients with HER-2 expressing peritoneal metastases (n=18)	Phase 1: IV. injection of 4 mg/kg trastuzumab followed by i.p. injection of 7.4-27.4 MBq/m² conjugate	Oranomed – based on radium-224	Acceptable pharmacokinetics, minimal distribution outside the peritoneal cavity, and limited toxicity	**NCT01384253** [2011 - 2016]

GRPR: gastrin-releasing peptide receptor, HER2: human epidermal growth factor receptor 2, MAD: multiple ascending dose, mCRPC: metastatic castrate resistant prostate cancer, MC1R: melanocortin 1 receptor, PRRT: peptide receptor targeting radioligand therapy. PSMA: prostate-specific membrane antigen, SSTR: somatostatin receptor, i.v.: intravenous, i.p.: intraperitoneal, p.i.: post-injection, ORR: objective response rate, N/A: not applicable

Figure 9: Whole-body volume rendered SPECT in PSMA+ (PC3 pip) and PSMA- (PC3 flu) tumors. The distribution of A) [212Pb]Pb-L2, B) [212Pb]Pb-L3 and C) [212Pb]Pb-L4 at 4 hours are depicted, with [212Pb]Pb-L2 showing the most optimal biodistribution for further evaluation (reprinted with permission from JNM. Banerjee et al., 2020,61:80-88. [93]).


Figure 10: A) PET/CT images taken with [18F]DCFPyl concurrently with SPECT/CT images of [212Pb]Pb-ADVC001 demonstrating superior dosimetry for salivary glands and kidney clearance for the lead-212 therapeutic. B) Sagittal and coronal images are presented after a 1.5-hour biodistribution time. This research was originally published in *JNM*. Griffiths et al. First-in-human 212Pb-PSMA-Targeted α-therapy SPECT/CT imaging in a patient with metastatic castration-resistant prostate cancer. J Nucl Med. 2024;65(4);664. © SNMMI [98].

Another PSMA-targeting agent, [212Pb]Pb-ADVC001 (Figure 10) is under evaluation in a phase 1/2 trial (NCT05720130). In this study, up to 18 patients will receive the radioligand in a maximum of four cycles, following a 3+3 dose escalation design. Cohort administered activities include 60 MBq, 120 MBq, 160 MBq, and 200 MBq of [212Pb]Pb-ADVC001. Once the recommended phase 2 activity is

determined, the study will advance to an expansion phase with three patient groups. One patient in the trial, a 73-year-old man, received 60 MBq of [212Pb]Pb-ADVC001 and underwent SPECT/CT imaging (photopeaks at 78 keV and 239 keV) at 1.5, 2, 20, and 28 h post-injection. Summed images reconstructed from both energy windows showed tumor biodistribution consistent with pretreatment [18F]F-DCFPyl PET/CT scans, together with low salivary gland uptake and rapid kidney clearance. These findings further demonstrate the feasibility and utility of lead-212 SPECT/CT imaging for assessing radiopharmaceutical biodistribution and enabling patient-specific dosimetry in the clinical development of lead-212-based TAT [98].

Fibroblast activated protein (FAP)

Another promising target gaining interest is fibroblast activation protein (FAP), predominantly expressed on cancer-associated fibroblasts (CAFs) within the tumor microenvironment. CAFs are known to promote tumor growth and metastasis, stimulate angiogenesis and suppress the immune response. Therefore, targeting CAFs may provide substantial therapeutic benefit beyond the eradication of neighboring tumor cells. Early therapeutic approaches have focused on lutetium-177-labeled FAP ligands [99]. However, lead-212 may be a more suitable option due to its shorter half-life, which better aligns with the relatively brief tumor retention time of early generation FAP ligands. Strategies to enhance tumor retention, such as multivalent FAP constructs and covalent binding approaches, are currently under investigation.

Clinical research

An upcoming clinical trial (NCT06710756) will evaluate the imaging and therapeutic potential of a lead-203 or lead-212-labeled cyclic peptide, PSV359, in patients with FAP-expressing solid tumors. However, no results have been reported so far.

C-X-C motif chemokine receptor 4 (CXCR4)

Activation of the C-X-C motif chemokine receptor 4 (CXCR4) by its ligand, C-X-C motif chemokine ligand 12 (CXCL12), drives tumor growth and metastasis [100]. Targeting the CXCR4/CXCL12 axis with [177Lu]Lu-Pentixather, a lutetium-177-labeled CXCL12-analogue, has demonstrated promising therapeutic efficacy in a limited group of patients with hematological malignancies, including multiple myeloma and lymphomas [101].

Clinical research

A lead-212-labeled version of Pentixather will be investigated in patients with atypical lung carcinoids, with two infusions administered six weeks apart (NCT05557708). To guide patient selection and assess treatment response, SPECT imaging with [203Pb]Pb-Pentixather will be performed before treatment and three months post-treatment.

Peptide-based radiopharmaceuticals

Somatostatin receptor (SSTR)

The treatment of SSTR-expressing neuroendocrine tumors (NETs) was significantly enhanced with the development of [177Lu]Lu-DOTATATE (Lutathera), which was the first EMA- and FDA-approved lutetium-177 based radiopharmaceutical. Based on this effective application of somatostatin analogues for peptide receptor targeting radiotherapy (PRRT) [102], investigations to optimize PRRT using alpha emitters, were initiated, including lead-212-based PRRT [103].

Preclinical research

Preclinical investigations demonstrated [212Pb]Pb-DOTAMTATE, in which the TATE vector peptide (Tyr^3-octreotate) is functionalized with TCMC as a chelator, to have a high tumor uptake in AR42J pancreatic tumor immunocompromised xenografts. Uptake in the pancreas and kidneys was shown to be a limiting factor, but it could be mitigated by nephroprotective strategies. Interestingly, a combination with the chemotherapeutic agent 5-fluorouracil, a well-known radiosensitizer, showed promising efficacy in this study [104]. Further optimization includes novel vector molecules like eSOMA-01, which demonstrated an optimal tumor-to-kidney uptake ratio (Figure 10) [56], and the incorporation of the PSC chelator via a PEG$_2$ linker in [212Pb]Pb-PSC-PEG-T (later renamed as VMT-α-NET), showing good tumor accumulation and retention with fast renal clearance. Moreover, this study highlighted the theranostic potential of the lead-203/lead-212 pair through SPECT imaging of [203Pb]Pb-VMT-α-NET confirming the biodistribution profile [55]. It has to be noted that not only did these compounds differ in their chelating strategies but also utilized different targeting peptides (octreotate vs octreotide).

When radiolabeling therapeutic radiopharmaceuticals, optimal molar activities remain an important consideration, and this was also demonstrated by Pretze and co-workers [105] through the measurement of effect of cellular uptake of a SSTR2 targeting [203/212Pb]Pb-PSC-PEG2-TOC (later renamed as VMT-α-NET). In this study a higher cellular uptake was proven with a rising molar activity with no limit found in the evaluated window

of molar activity. Whilst the broader application of this study on 212Pb-radiopharmaceuticals (preclinical and clinical) remains to be determined, we feel it is important to highlight that the influence of molar activity on tumour accumulation should always be considered during the development of novel therapeutic radiopharmaceuticals.

Clinical research

The first lead-212-labeled SSTR-targeting ligand to reach clinical trials was [212Pb]Pb-DOTAMTATE (AlphaMedix™). In a phase 1 injected activity escalation study (NCT03466216), [212Pb]Pb-DOTAMTATE was administered i.v. to 20 patients with histologically confirmed NETs expressing SSTR without prior history of RNT [106]. After single ascending amounts of activity with an increment of 30% and a multiple ascending injected activity regimen, the recommended regimen for a phase 2 study was four cycles of i.v. administered 2.5 MBq/kg [212Pb]Pb-DOTAMTATE at eight-week intervals. Of the ten subjects receiving the highest amount of activity, eight showed an objective, long-lasting radiologic response according to [68Ga]Ga-DOTATATE PET/CT scans (Figure 11). The treatment was well tolerated, with mild adverse events such as nausea, mild hair loss, abdominal pain, diarrhea, and fatigue being observed. These encouraging results led to the ongoing phase 2 study (NCT05153772) in which 66 subjects with or without prior TRT history are included. Preliminary results demonstrate an objective response rate (ORR) of 47.2% [107]. When pooling data from both phase 1 and phase 2 trials, the ORR increases to 50%, surpassing the 18% ORR reported for [177Lu]Lu-DOTATATE in the phase 3 NETTER-1 study [102]. The latest results were presented at the European Society for Medical Oncology (ESMO) meeting in October 2025, with separated results for previously treated and PRRT-naïve patients. In 35 PRRT-naïve patients, of whom 86% were able to receive all 4 intended administrations, there was a 60% ORR with an impressive disease control rate (DCR) of 94% and an equally impressive duration of response (DoR) of ≥ 24 months in 72% of the 21 responding patients [108]. The PFS rate at 36 months was 73% as assessed by local investigators, the 36 months overall survival (OS) rate was 88%. These findings suggest that targeting SSTR-expressing tumors with alpha-emitting radioligands might outperform the current PRRT therapies utilizing beta-emitters. However, in 17/35 (49%) PRRT-naïve patients dysphagia was described (grade 3 in 1 patient, no grade 4), with an "achalasia-like" presentation and responsiveness to botox injections [107,108]. Furthermore, 13/35 (37%) of patients developed a renal event, of which 6 (17%) grade ≥ 3. Further long term follow-up and larger clinical trials will have to demonstrate the safety profile of this radiopharmaceutical in this setting.

In another 26 patients previously treated with PRRT, of whom 84% received all 4 intended therapy administrations, a 35% ORR was observed, with an impressive DCR of 96% and a DoR of ≥18 months in all 9 responding patients [109]. The 18-month PFS rate was 83% and the 18-month OS rate was 85%. Dysphagia was again observed, in 15/26 (58%) of patients, of whom 4 (15%) grade 3 (no grade 4). Only 2 of the 26 patients (8%) showed renal adverse events, both grade ≥ 3 [108,109]. No cases of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) were reported in both cohorts (pre-treated or PRRT-naïve) [108,109]. Taken together, [212Pb]Pb-DOTAMTATE has the potential to become a clinically meaningful therapeutic choice in NET patients, either as first PRRT agent or in PRRT pre-treated patients upon progression.


Figure 11: The biodistribution of [203Pb]Pb-eSOMA-01 in A) SPECT/CT scans of H69 human small cell lung cancer-bearing mice at different time points up to 24 hours and B) tumor/kidney ratios derived from the SPECT images (Reprinted under the terms and conditions of the Creative Commons Attribution license (CC BY) from [56]). Note that the compound [203Pb]Pb-eSOMA-2 mentioned in the figure, is a less optimal compound, not discussed.

Another SSTR-targeting ligand under clinical development is VMT-α-NET (previously named PSC-PEG-TOC). A personalized approach has been investigated during clinical evaluation of [212Pb]Pb-VMT-α-NET, involving a preliminary dosimetry step with its theranostic partner [203Pb]Pb-VMT-α-NET, which is evaluated either in a separate study (NCT05111509) or in an integrated sub-study (NCT05636618). A first case study reported the biodistribution and scintigraphy images of [212Pb]Pb-VMT-α-NET in a 75-year-old woman with advanced G2 Net of unknown primary [110]. In an early phase 1 trial (NCT05111509), ten patients with beta-PRRT-relapsed or refractory gastro-entero-pancreatic NETs received 185 MBq of [203Pb]Pb-VMT-α-NET i.v., followed by SPECT/CT imaging at 1, 4-8, 24-30, and 42-52 hours post-injection. Three participants were also administered nephroprotective amino acids (lysine and arginine) over four hours and scheduled for subsequent treatment with [212Pb]Pb-VMT-α-NET as part of a separate phase 1 trial (NCT06148636).

Imaging results from [203Pb]Pb-VMT-α-NET were compared to those of gallium-68 [68Ga]Ga-DOTA-TATE or [68Ga]Ga-DOTA-TOC, and organ-level MIRD dosimetry calculations were used to predict critical organ doses for [212Pb]Pb-VMT-α-NET. Predicted organ doses were 14.3 ± 4.6 mGy/MBq for the kidneys, 8.4 ± 4.1 mGy/MBq for the spleen, 2.4 ± 0.8 mGy/MBq for the liver, and 0.59 ± 0.11 mGy/MBq for blood. Based on these calculations, three patients who received nephroprotective amino acids were administered cumulative [212Pb]Pb-VMT-α-NET activities of 196.1, 270.1, and 492.1 MBq, respectively, over two cycles to reach the target renal dose of 3.5 Gy for the first cohort of the phase 1 trial (NCT06148636) [111]. Another study reports the investigation of [203/212Pb]Pb-VMT-α-NET in a larger cohort of patients (12 patients). It was found that imaging with [203Pb]Pb- VMT-α-NET followed by a single dose of [212Pb]Pb- VMT-α-NET was well tolerated with promising efficacy [112].

In the ongoing integrated phase 1 trial testing the theranostic pair [212Pb]Pb-VMT-α-NET and [203Pb]Pb-VMT-α-NET (NCT05636618), up to 160 patients with NETs that were not previously treated with TRT will be recruited. In the first two cohorts, subjects received 200 MBq of [203Pb]Pb-VMT-α-NET for dosimetry evaluation before [212Pb]Pb-VMT-α-NET treatment. SPECT/CT imaging was performed up to 24 hours post-injection, and participants received up to four treatment cycles of [212Pb]Pb-VMT-α-NET, co-administered with nephroprotective amino acids, spaced eight weeks apart. Recently, at ESMO 2025, results on 55 treated NET patients have been presented (2 treated with 92.5 MBq/cycle, 46 with 185 MBq/cycle and 7 with 222 MBq/cycle) [113]. The most common treatment-emergent adverse event was lymphocytopenia, observed in 33% of patients (minority grade 3, no grade 4). No activity limiting toxicities nor grade 4/5 adverse events were reported. Interestingly, there were no serious renal complications and no dysphagia. Objective partial response was seen in 8/23 (35%) evaluable patients in cohort 2 (185 MBq/cycle) with ≥ 9 months follow-up, with stable disease in 14/23 (61%) and one patient with a non-interpretable scan. The ORR increased to 44% in patients with SSTR2 positivity in all tumoral lesions (n = 16). The 2 patients treated with 92.5 MBq/cycle still had stable disease ≥ 18 months after treatment [113]. Further clinical investigation of this clearly promising radiopharmaceutical is ongoing. Furthermore, two additional clinical trials (NCT06479811 and NCT06427798) investigating [212Pb]Pb-VMT-α-NET in patients with SSTR-expressing tumors are expected to start recruitment in 2025.

Melanocortin-1 receptor (MC1R)

Melanotropin peptide analogues targeting the melanocortin-1 receptor (MC1R), which is overexpressed in melanoma cells, have been explored as vector molecules for lead-203/lead-212 theranostics [114].

Preclinical research

The radiolabeled peptide targeting MC1R, [212Pb]Pb-DOTA-Re(Arg11)CCMSH, demonstrated rapid tumor uptake, prolonged tumor retention, and injected activity-dependent survival benefit in B16/F1 melanoma-bearing immunocompetent xenografts [114]. The lead-203 counterpart, [203Pb]Pb-DOTA-Re(Arg11)CCMSH (Figure 12) confirmed the promising pharmacokinetics and suitability as a theranostic pair [115]. Another MC1R targeting peptide, [203Pb]Pb-DOTA-GGNle-CycMSH_{hex} demonstrated a favorable accumulation and good imaging properties in both immunocompetent subcutaneous B16/F1 and B16/F10 mouse models, as well as in a B16/F10 pulmonary metastatic melanoma mouse model [116]. Lastly, [212Pb]Pb-VMT01, also targeting the MC1R receptor, showed to reduce tumor growth in B16/F10 melanoma-bearing immunocompetent mice. Biodistribution of the [203Pb]Pb-VMT01 theranostic counterpart showed rapid tumor accumulation with off-target accumulation primarily localized in the kidneys. Interestingly, based on the induced immunological cell death by TAT, this study reported additional tumor cytotoxicity when combining [212Pb]Pb-VMT01 administration with immune

checkpoint inhibitor therapy [117].

Clinical research

A theranostic approach involving lead-based radioligands was evaluated for MC1R-expressing metastatic melanoma patients. This strategy employed the theranostic pair [203Pb]Pb-VMT01 for patient selection and dosimetry assessment and [212Pb]Pb-VMT01 for TAT. The imaging TIMAR1 trial (NCT04904120) used a cross-over design in stage IV melanoma patients, who received randomized, sequential i.v. injections of activities of 555-925 MBq [203Pb]Pb-VMT01, followed by SPECT/CT imaging at 1, 4, and 24 h post-injection, and 74-277 MBq [68Ga]Ga-VMT02, with PET/CT imaging performed dynamically up to one hour and at two and three hours post-injection, approximately one month apart. Only three subjects underwent imaging with [203Pb]Pb-VMT01.

The experimental tracer [68Ga]Ga-VMT02 successfully identified MC1R-positive tumors in three out of six subjects, facilitating patient selection for future [212Pb]Pb-VMT01 therapy trials [118]. SPECT/CT imaging demonstrated tumor retention of [203Pb]Pb-VMT01 at 24 h, supporting organ and tumor dosimetry calculations applicable to [212Pb]Pb-VMT01 treatments. Subsequently, a phase 1/2 study (NCT05655312) evaluating [212Pb]Pb-VMT01, incorporated positive [203Pb]Pb-VMT01 or [68Ga]Ga-VMT02 imaging as an inclusion criterion [119]. This injected activity escalation and injected activity expansion study plans to enroll up to 264 subjects,

who will receive up to 555 MBq [212Pb]Pb-VMT01 i.v., either as monotherapy or combined with the programmed cell death protein 1 (PD-1) inhibitor nivolumab, administered for up to three treatment cycles eight weeks apart. Nephroprotective amino acids will be co-administered. In the initial cohort, patients received 111 MBq of [212Pb]Pb-VMT01, while the ongoing second cohort utilizes 185 MBq [119]. Recently, the FDA granted fast-track designation to [212Pb]Pb-VMT01 in melanoma [120].

Gastrin-releasing peptide receptor (GRPR)/bombesin receptor subtype 2 (BB2)

The gastrin-releasing peptide receptor (GRPR), also known as bombesin receptor subtype 2 (BB2), is expressed in various tumors, including prostate, breast, lung, colorectal, cervical cancers, and cutaneous melanoma. Moreover, expression of GRPR/BB2 is limited in healthy tissues, providing a good rationale for GRPR/BB2 targeted RNT [121].

Preclinical research

The RM2 peptide targeting the BB2 receptor, expressed in prostate cancer, consists of the structure DOTA-4-amino-1-carboxymethyl-piperidine-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH$_2$. This peptide has been radiolabeled with both lead-203 and lead-212 for preclinical evaluation. [203Pb]Pb-RM2 was shown to exhibit long-term tumor retention and great complex stability up to 24 hours post injection in PC-3 immunocompromised xenografts [122]. Tumor targeting was confirmed following administration


Figure 12: Maximum intensity projection (MIP) images of [68Ga]Ga-DOTATATE PET/CT images of the first ten subjects before treatment (left scan of each patient) and after receiving four cycles of [212Pb]Pb-DOTAMTATE therapy (right scan of each patient) at an injected activity level of 2.5 MBq/kg for each cycle [Reprinted with permission from JNM, Delpassand et al., 2022;63:1326-1333. [106]].

with the therapeutical radiopharmaceutical [^{212}Pb]Pb-RM2. Furthermore, treatment of immunocompromised prostate cancer (PC-3)-bearing mice indicated good tolerability and temporary control of tumor growth [123].

Clinical research

A ^{212}Pb-labeled GRPR antagonist, [^{212}Pb]Pb-DOTAM-GRPR1, is currently under investigation in a phase 1 study (NCT05283330) for subjects with recurrent or metastatic GRPR-expressing tumors, who have not previously received PRRT. The injected activity escalation phase follows a 3+3 design, with activity increments of approximately 30% in subsequent cohorts. The maximum allowable total injected activity per cycle is 203.5 MBq. In the multiple-ascending injected activity regimen, participants may receive up to 888 MBq over four cycles. Once the recommended multiple-ascending activity is determined, patients will receive up to four cycles of [^{212}Pb]Pb-DOTAM-GRPR1 at eight-week intervals. No results have been published to date.

Antibody-based radiopharmaceuticals

Human epidermal growth factor receptor 2 (HER2)

Antibodies have been extensively studied as targeting vectors for lead-212 based TAT in preclinical research, with most research focusing on human epidermal growth factor receptor 2 (HER2) targeting constructs. HER2 is found to be overexpressed in approximately 20–30% of breast cancers, as well as a substantial proportion of ovarian, gastric and lung adenocarcinomas, and can be correlated with poor prognosis in these patients [124].

Preclinical research

Early work by Horak *et al.* [125] evaluated [^{212}Pb]Pb-DOTA-AE1 in murine SK-OV-3 ovarian cancer-bearing immunocompromised mice. Herein, the AE1 targeting vector consisted of an IgG2a murine monoclonal antibody targeting the HER2/neu receptor. Treatment with [^{212}Pb]Pb-DOTA-AE1 was shown to halt the development of small tumor growth but was ineffective in larger tumors [125]. A major limitation of this study is the potential release of bismuth-212 from the DOTA complex during lead-212 decay (36%), resulting in increased renal toxicity, as well as high bone marrow suppression after i.v. injection due to long blood half-life [125].

Milenic *et al.* successfully radiolabeled trastuzumab (Herceptin), an FDA and EMA-approved humanized monoclonal antibody, with lead-212 using TCMC. Therapeutic efficacy was demonstrated in immunocompromised LS-147T colon and Shaw pancreatic carcinoma models [126]. Follow-up studies in LS-174T-bearing immunosuppressed mice revealed that [^{212}Pb]Pb-TCMC-trastuzumab increased double-stranded DNA breaks, leading to DNA repair inhibition, G2-M cell cycle arrest, and chromatin remodeling [127]. The same group later demonstrated that combination therapies with [^{212}Pb]Pb-TCMC-trastuzumab enhance therapeutic efficacy. In immunocompromised preclinical models, pairing [^{212}Pb]Pb-TCMC-trastuzumab with gemcitabine increased survival and apoptosis in S-phase arrested cells [128,129]. Paclitaxel pretreatment improved survival 3.9-fold [130], while pretreatment with carboplatin enhanced median survival up to 7.9-fold. However, combination response was highly dependent on the administration timing in LS-174T-bearing immunocompromised mice [131].

Another group further evaluated [^{212}Pb]Pb-TCMC-trastuzumab as a treatment for prostate cancer. Herein, i.v. administration resulted in decreased tumor growth in mice bearing human PC-3MM2 prostate tumors, which express HER2 in low levels. Prolonged survival with no toxicity was also reported [132]. The biodistribution and toxicity of [^{212}Pb]Pb-TCMC-trastuzumab was analyzed in nonhuman primates, 8 hours, 10 days or 90 days post administration. Up to 48 hours after i.p. injection of the treatment, 95.5 ± 5.0% of activity was retained in the peritoneal cavity as determined by quantitative gamma camera imaging, with no treatment-related toxicity observed [133]. These preclinical data on [^{212}Pb]Pb-TCMC-trastuzumab have supported further clinical trials.

Clinical research

The first phase 1 clinical trial (NCT01384253) involving the use of lead-212 as the cargo for TAT was conducted in 2014, employing [^{212}Pb]Pb-TCMC-trastuzumab in patients with HER2 expressing peritoneal carcinomatosis. These patients received 4 mg/kg trastuzumab i.v., followed by a single i.p. injection of 7.4 MBq/m^2 [^{212}Pb]Pb-TCMC-trastuzumab to evaluate the conjugate's distribution, pharmacokinetics, and safety profile. Whole-body gamma scans indicated minimal redistribution out of the peritoneal cavity and minimal uptake in normal organs [134]. Subsequently, an activity-escalation trial was initiated, involving 18 patients (16 females with recurrent HER-2 positive ovarian cancer and two males with HER2-positive colon cancer), who were administered escalating activities of 7.4 to 27.4 MBq/m^2 with a 30% increase for each subsequent activity level [135]. The ascending administered activities did not result in significant drug-related toxicities, consistent with the dosimetry analysis. At six weeks post-administration, ten of the 18 patients

achieved stable disease, while eight out of 18 showed disease progression. Stable disease was notably observed in nine out of 10 patients receiving injected activities of 12.6 MBq/m² or higher. Overall, up to 27.4 MBq/m² of [212Pb]Pb-TCMC-trastuzumab administered i.p. was well tolerated, and further activity escalation studies were suggested as a feasible strategy to enhance tumor response [136].

HER1/Epidermal growth factor receptor (EGFR)

Besides the HER2 targeting antibody trastuzumab, other antibodies have also been evaluated as vector molecules. For example, two antibodies, cetuximab [137] and panitumumab [138], have been explored preclinically, both targeting the epidermal growth factor receptor (EGFR), also known as HER1, which is found to be overexpressed in several cancers.

Preclinical research

In an immunocompromised LS-174T colon carcinoma mouse model, [212Pb]Pb-TCMC-cetuximab significantly improved the median survival compared to an 212Pb-isotype control. Moreover, pretreatment with gemcitabine, 24 hours before [212Pb]Pb-TCMC-cetuximab administration, resulted in further prolongation of the median survival in tumor-bearing mice, while concomitant treatment with carboplatin and [212Pb]Pb-TCMC-cetuximab demonstrated lower efficacy. Dual targeting of HER1 and HER2 using [212Pb]Pb-TCMC-cetuximab and [212Pb]Pb-TCMC-trastuzumab, respectively, showed similar therapeutic benefits in this study [137]. [212Pb]Pb-TCMC-panitumumab demonstrated superior therapeutic effects in immunocompromised LS-174T tumor xenografts compared to [212Pb]Pb-TCMC-cetuximab or the HER2 targeting [212Pb]Pb-TCMC-trastuzumab. Prior treatment with either gemcitabine or paclitaxel potentiated the beneficial effect of [212Pb]Pb-TCMC-panitumumab alone. The multimodal therapy regime in which topotecan was administered 24 hours prior and 24 hours post [212Pb]Pb-TCMC-panitumumab resulted in the greatest therapeutic response in this study [138].

[203Pb]Pb-TCMC-panitumumab-F(ab')₂, the F(ab')₂ fragment of the anti-HER1 antibody, panitumumab, showed similar biodistribution and tumor uptake in immunocompromised LS-174T tumor xenograft mice compared to the full-length antibody, [203Pb]Pb-TCMC-panitumumab. However, due to their smaller size, F(ab')₂ fragments have the advantage of faster pharmacokinetics which aligns better with the relatively short half-life of lead-212, and reduced immunogenicity and off target toxicity relating to the lack of the Fc region. Moreover, therapeutic efficacy was similarly proven after treatment of these mice with [212Pb]Pb-TCMC-panitumumab-F(ab')₂. The combination with either gemcitabine or paclitaxel with [212Pb]Pb-TCMC-panitumumab-F(ab')₂ also similarly potentiated the effect on median survival [87].

Other targets

Preclinical research

The lead-203/lead-212 theranostic strategy was applied to CD20-targeting rituximab in non-Hodgkin lymphoma. Tumor retention was demonstrated in immunocompetent EL4-hCD20-Luc bearing mice, but also some off-target uptake in healthy organs. [212Pb]Pb-TCMC-rituximab extended survival in both early and late-stage disease [139]. Similarly, for the treatment of non-Hodgkin lymphoma, the CD37-targeting antibody [212Pb]Pb-NNV003 showed survival benefits in immunocompromised MEC-2 and Daudi tumor models, though biodistribution revealed rapid uptake in some healthy tissues and slow tumor uptake [84]. One study reported marked tumor growth inhibition in immunosuppressed RPMI8226-bearing mice after [212Pb]Pb-TCMC-daratumumab (Figure 13) treatment targeting CD38 in multiple myeloma. However, acute toxicity was reported after i.v. administration at injected activities larger than 277.5 kBq [140].

A theranostic approach using the melanin-targeting antibody c8C3 showed localized tumor uptake of [203Pb]Pb-TCMC-c8C3 in immunocompetent B16-F10 melanoma-bearing mice, with the therapeutic analogue [212Pb]Pb-TCMC-c8C3 slowing tumor growth in an injected activity-dependent manner. However, high administered activities of the non-targeting control yielded similar benefits in this study [141].

The B7-H3 targeting antibody [212Pb]Pb-TCMC-376.96 was evaluated in two immunocompromised ovarian cancer mouse models bearing i.p. ES-2 or A2780cp20 tumors. [212Pb]Pb-TCMC-376.96 accumulated in ascites cells and tumors and prolonged survival in an injected activity-dependent manner, while co-treatment with carboplatin showed no added benefit [133]. In pancreatic cancer, administration of [212Pb]Pb-TCMC-376.96 in both a patient-derived s.c. Panc039 xenograft model and an orthotopic PDAC3 mouse model resulted in significant tumor uptake and reduced tumor growth in the two immunocompromised models respectively [142].

Figure 13: The whole-body (A) and transaxial (B) images of [^{203}Pb]Pb-DOTA-Re(Arg^{11})CCMSH 2 hours post-injection in B16/F1 murine melanoma-bearing mice (Reprinted with permission from [115]. This research was originally published in JNM. Miao et al. J Nucl Med. 2008;49:823-829).


Figure 14: Serial SPECT/CT images of the biodistribution of [^{203}Pb]Pb-TCMC-daratumumab targeting CD38 in RPMI8226 (multiple myeloma) bearing mice (Reprinted with permission, [140]).

For triple-negative breast cancer (TNBC), the CSPG4-targeting [^{212}Pb]Pb-TCMC-225.28 inhibited tumor growth in immunosuppressed SUM159 xenograft models [143]. Another TNBC therapy, [^{212}Pb]Pb-TCMC-αVCAM-1, targeting VCAM-1 in brain metastases, showed a 6-fold higher tumor uptake than healthy brain tissue and significantly reduced metastasis burden compared to standard external beam radiotherapy [51].

In prostate cancer, [^{212}Pb]Pb-TCMC-YS5,

targeting CD46, inhibited tumor growth and prolonged survival in PC3 and patient-derived xenograft models [144]. For osteosarcoma, [212Pb]Pb-TCMC-TP-3, targeting p80, reduced OHS cancer spheroid size *in vitro*, with a proposed dual-alpha strategy combining it with radium-224 [145]. In this approach, the bone-seeking radium-224 provides localized irradiation to the osteoblastic matrix, while lead-212, coupled to the osteosarcoma-specific antibody, delivers additional targeted alpha radiation to the tumor cells. In this way, bone tropism and tumor-specific antigen binding are exploited simultaneously to enhance the therapeutic reach of alpha therapy.

I.p. administration of the CD146 targeting murine antibody mOI-3 radiolabeled to lead-212, [212Pb]Pb-TCMC-mOI-3, resulted in improved median survival in mice mesothelioma xenografts [146]. Similarly, i.p. treatment of [212Pb]Pb-TCMC-chOI-1 targeting protein tyrosine kinase 7 (PTK7) was evaluated for the treatment of ovarian cancer, showing tumor retention and uptake into the systemic blood circulation after i.p. injection. Moreover, [212Pb]Pb-TCMC-chOI-1 was shown to decrease tumor growth and significantly prolonged survival in two separate immunosuppressed ovarian cancer mouse models [47,147].

Pretargeting

Preclinical research

Interestingly, pretargeted TAT has been explored in a study by Shah *et al.* in which the administration of the antibody vector was decoupled from the administration of the radionuclide. Utilizing the inverse electron demand Diels-Alder reaction, a tetrazine (Tz) coupled to a chelator, DOTA-Tz or TCMC-Tz, radiolabeled with lead-212 was injected in immunocompromised LS174T bearing mice after pretreatment with the *trans*-cyclooctene (TCO) conjugated CC49 antibody targeting tumor associated glycoprotein 72 (TAG-72). Biodistribution was superior for the [212Pb]Pb-DOTA-Tz compared to [212Pb]Pb-TCMC-Tz. A reduction in tumor size was seen using the CC49-TCO and [212Pb]Pb-DOTA-Tz combination with significantly improved survival *in vivo*, demonstrating the high potential of pretargeted TAT with lead-212 [148]. A similar study was performed by Bauer *et al.* in which the TCO conjugated antibody 5B1, targeting carbohydrate cell surface antigen 19-9, followed by administration [212Pb]Pb-DO3A-PEG7-Tz three days later resulted in prolonged survival and delayed tumor growth in immunosuppressed s.c. BxPC-3-bearing mice [149].

Other vectors

Inorganic carrier systems (Microparticles)

Another approach for 212Pb-based therapy was introduced by Li *et al.* in 2021 [88]. They coupled the radionuclide lead-212 to a carrier vehicle consisting of calcium carbonate ($CaCO_3$) microparticles (MP) for the treatment of disseminated disease in bodily cavities such as the peritoneal cavity.

Preclinical research

The stability of [212Pb]Pb-$CaCO_3$-MP was confirmed after i.p. injection in tumor-free mice as limited redistribution to the kidneys, spleen, and liver was noted. Treatment of immunocompromised ES-2 ovarian cancer-bearing mice with [212Pb]Pb-$CaCO_3$-MP using i.p. administration resulted in a significant survival benefit, which appeared to be dependent on amount of injected activity. However, in this study i.p. injection of unbound [212Pb]Pb-Cl_2 also produced some therapeutic effect [88].

Alternative carriers have been discussed in the review by Scaffidi-Muta and co-workers [13]. In such cases, lead-212 is incorporated into large constructs such as colloids, fullerene nanoconstructs, liposomes, and other types of nanoparticles. As an example, fullerenes have been explored in the early 2000s [150,151]. Liposomes have also been formulated [152,153] but were not translated into *in vivo* studies. In a previous literature review, we discussed the pitfalls for translation of alpha-radionuclide containing nanotechnology [154]. The first major hurdle remains the lack of large-scale production methods that allow precise manufacturing at scale in compliance with GMP requirements. The second obstacle is that the size of these nanotechnologies must be strictly controlled to minimize splenic, hepatic and pulmonary accumulation, thereby reducing toxicity risks. Regulatory challenges of nanoparticles for medical application are a well-established hurdle and have been reviewed in detail [154]. Finally, formulation in nanoparticles might change the toxicity profile of the radionuclides, and this also warrants more precise and cost-intensive investigations [154].

Prospects and Future Directions for Lead-212 and Lead-203

Lead-212 has gained considerable interest in the evolving field of TAT. TAT is highly cytotoxic, delivering high LET over a short range in biological tissue, leading to double-stranded DNA breaks, complex chromosomal aberrations, and direct killing of cells by destruction of cellular components other than the DNA which also affects cell survival. These

characteristics make TAT ideal for the treatment of minimal residual tumors or micro-metastatic disease. Moreover, unlike beta emitters, alpha emitters are less dependent on the oxidation state of malignant cells. Therefore, alpha emitters may offer a therapeutic alternative, specifically when beta-minus emitters become ineffective due to the development of radioresistance. Lead-212 is valuable for TAT because it functions as an *in vivo* alpha-particle generator, decaying into bismuth-212. During its decay both beta and alpha radiation is emitted, though the energy contribution of this beta particle is negligible compared to the alpha particle at the currently used clinically administered activities.

Key advantages of lead-212 for TAT include its relatively short half-life, which allows for maximum energy deposition in the cancer cells, while also reducing the burden of radioactive waste, yet still allowing for feasible production [3,12]. Moreover, its diagnostic partner, lead-203, can be used for SPECT imaging, making it a versatile tool for theranostic applications. It is currently believed that lead-212 does have a realistic chance to be used on a large scale in nuclear medicine within the next decade [3,12].

Production, availability and position among alpha emitters

Lead-212 is produced through various methods, all involving the separation of the radionuclide from thorium-228, radium-224, and various radionuclides throughout a complex decay chain. Advantages of lead-212 include logistics, due to the availability through either the form of $^{212}Pb(HNO_3)_2$ eluate (with a reasonable physical half-life of 10.6 hours) or in various generator systems based on a column separation or gaseous radon-220 emanation for the decentralized delivery of lead-212. More than 15 companies across Europe, North America, Asia, and Oceania are involved in the drive to promote lead-212 for preclinical validation and clinical applications [3,12].

The availability of the cyclotron produced lead-203 as a SPECT imaging agent allows for accurate dosimetry planning and can be an optimal theranostic partner for lead-212 during preclinical development and early clinical trials. Currently, the widespread clinical implementation of lead-203 as a theranostic derivative is not foreseen. This is due to the expensive infrastructure required for the cyclotron production of lead-203. Other routine theranostic partners could still include gallium-68 and fluorine-18 based tracers [3,4].

Several trials have validated the applicability of lead radioisotopes in a clinical setting. However, within TAT one radionuclide is unlikely to fit each clinical need. Lead-212 thereby complements other promising radionuclides such as actinium-225 and astatine-211 within the alpha emitter landscape. For example, the shorter half-life of lead-212 (10.6 h) compared to actinium-225 (~10 days) may be beneficial for reducing off-target toxicities, while actinium-225 leads to a higher absorbed dose (through four consecutive alpha-emissions) and hence higher damaging capacity per decay which may be beneficial in some indications. However, in both cases a crucial component is the retention of the alpha-emitting daughter radionuclides at the target site [155]. In contrast to astatine-211, which is cyclotron-produced and requires centralized production, facing logistical challenges, lead-212 can be sourced from generator systems, offering a solution to availability in certain areas [53].

Radiochemistry, chelation and dosimetry

A key factor in advancing lead-212-based therapies is the availability of robust chelators. Currently, TCMC is the best commercially available candidate and has demonstrated the highest *in vivo* stability for lead-212 chelation to date. However, many novel chelators are under active development. However, a disadvantage for lead-212, compared to therapies that are not based on *in vivo* generator radionuclides, is that the efficacy of the alpha emitter requires the radiopharmaceutical to remain stable upon beta decay. Otherwise, chemical instability may cause the release of the alpha emitting daughter, bismuth-212, which tends to accumulate in the kidneys [156]. Furthermore, even though the effect of recoil is of lower magnitude with beta minus emissions compared to alpha emissions, it may still lead to the release of a percentage of bismuth-212 upon decay. Indeed, more optimal chelators need to be developed, or quick accumulation and strong trapping in the target is needed to allow the full deposition of the alpha emission in the tumor [3,30].

Diagnostic quantification of dosimetry with lead-203 will not consider the kidney exposure due to bismuth-212 that is released, and therefore, dosimetry with lead-212 remains necessary for accurate kidney dose estimation, as lead-203 studies do not account for bismuth-212 release. Since the stability of ^{203}Pb- and ^{212}Pb-radiopharmaceuticals can differ significantly, direct comparisons require careful evaluation [29,83,157].

Vector optimization

It is essential to match the pharmaceutical half-life of lead-212 to the biological half-life of the vector to maximize the total amount of energy deposited in the tumor and minimize off-target

irradiation upon systemic administration. Given the relative short half-life of lead-212, vectors with intermediate to fast pharmacokinetics are preferred, including antibody fragments, peptides or even small molecules. However, other vectors, such as full-length antibodies or inorganic microparticles, can also find their place in lead-212 based TAT through localized administration or pretargeting strategies, altering the biological distribution of the vector [3,53].

Safety, toxicological and regulatory challenges

Despite the therapeutic promise, several safety and operational challenges remain. The high-energy gamma-ray emitted by thallium-208 during decay of lead-212 should also be considered to allow for radiation safety during radiopharmaceutical production, dispensing and administration [3,34]. When working with lead-212 generators in the clinic, it is important that the consideration of radon-220 during generator use is investigated. In a recent study by Pretze and co-workers, the emanation system from CERN and the wet-chemical system from Perspective Therapeutics was evaluated with respect to radon-220 release. It was found that measurable radon-220 was only released during generator elution and not storage, and that the emanation-based generators are more prone to release than the wet-chemical system generators [46].

Moreover, the short half-life of lead-212 can cause high dose depositions *in vivo* at a relatively high dose rate, without requiring prolonged long retention (> 5 days). This can be advantageous when the radionuclide localizes within the tumor; however, it also poses a risk to healthy organs, such as the kidneys, where unintended accumulation may occur. Therefore, pharmacokinetics of each radiopharmaceutical construct need to be carefully optimized using accurate dose estimation tools and dosimetric models [53].

To ensure batch-to-batch consistency of each lead-212 or lead-203 radiopharmaceutical, regulations on Good Manufacturing Practice (GMP)-compliant production chains need to be implemented as well as reliable Quality Assurance protocols that relate to primary standards. Other logistical hurdles include a well-coordinated supply and distribution of the radiopharmaceutical, especially for lead-212, given its relatively short half-life [3]. Examples of GMP-complaint production methods are available in literature [38,48].

Radiobiological research

Research towards lead-212-based TAT has been explored using various targeting vectors as discussed in this review. This radiobiological research should take into account the pharmacological half-life of such vector molecules relating to the half-life of lead-212. However, altering the administration route of the TAT may overcome any discrepancies but should be extensively evaluated using proper biodistribution studies. Fractionated or repeated administration of lead-212 based therapy can also be explored. Even though the direct killing effect of alpha emitters may not be increased using repeated administrations, benefit may come from the increased chance of complete tumor eradication following repeated injections. Moreover, fractionating the therapy can be advantageous for reducing off target toxicity.

In addition, besides the direct cytotoxic effect of TRT, indirect effects should also be further explored using rationally designed preclinical studies. Such effects including the abscopal and bystander effects can only be explored in immunocompetent mice models, while current models used in the field are predominantly immunocompromised.

Clinical trial design and patient selection

The design of clinical trials is vital for a successful translation of lead-212-based therapies. Multicenter, prospective, controlled studies with coordinated protocols are needed to generate high-quality, reproducible results that can lead to registration by EMA, FDA and other authorities and incorporation in clinical guidelines. Patient selection should be biomarker-driven, including theranostic imaging and all clinically relevant criteria, including prior treatments, should be considered.

Next-generation strategies: pretargeting and combination therapies

Irradiation of healthy tissues and long systemic circulation related to the size of the vector molecule may be reduced through separation of the targeting and *in vivo* radiolabeling using a pretargeting approach. Herein, the non-bound vector is administered first, allowing tumor accumulation and clearance from the systemic circulation before administration of the radiopharmaceutical, which has a strong and rapid interaction with the target-bound vector molecule. Early-stage preclinical studies have shown promising results using this strategy for lead-212 based TAT [148,149].

Further, TAT may gain additional therapeutic efficacy when rationally combined with other treatment modalities. For example, TAT has been reported to stimulate the immune system through immunogenic cell death, triggering systemic responses that enhance therapeutic efficacy [10,158]. This indicates potential synergy with immunotherapy such as immune checkpoint inhibitors [158].

Moreover, the impact of TAT on DNA damage suggests potential benefit from combinations with other treatments influencing the DNA damage or repair such as PARP-inhibitors or chemotherapy. Early-stage research into these types of combinations is ongoing [158].

Conclusions

Lead-212 and lead-203, represent promising radioisotopes for TAT and diagnostic imaging, respectively. Accumulating preclinical and clinical data support the therapeutic potential of lead-212 across multiple cancer types. Its theranostic counterpart, lead-203, plays a valuable role in the translational phase, enabling optimization of treatment schedules and dosimetry for lead-212-based therapies. Continued progress in radiochemistry, vector development, and patient stratification is expected to further expand the clinical impact of these isotopes. Lead-based radiopharmaceuticals are well positioned to play a central role in the future of precision oncology.

Abbreviations

BB2: Bombesin receptor subtype 2

CAFs: Cancer-associated fibroblast

CERN: Conseil européen pour la Recherche nucléaire

CXCR4: C-X-C motif chemokine receptor 4

DNA: Deoxyribonucleic acid

DOTA: 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid

DOTAM: 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetamide

EDTA: Ethylenediaminetetraacetic acid

EGFR: Epidermal growth factor receptor

FAP: Fibroblast activating protein

FDA: United States Food and Drug Administration

GPRP: Gastrin-releasing peptide receptor

HCl: Hydrochloric acid

HDEHP-teflon: Di-(2-ethylhexyl) phosphoric acid

HER2/1: Human epidermal growth factor receptor 2/1

HNO_3: Nitric acid

i.p.: Intraperitoneal

keV: Kiloelectronvolt

LET: Linear energy transfer

MC1R: Melanocortin-1 receptor

mCRPC: Metastatic castrate-resistant prostate cancer

MeV: Megaelectronvolt

MP: Microparticles

NaI: Sodium iodide

NET: Neuroendocrine tumors

PSC: Lead-specific chelator

PET: Positron emission tomography

PSMA: Prostate-specific membrane antigen

PTK-7: Protein tyrosine kinase 7

RNT: Radionuclide therapy

SPECT: Single-photon emission computed tomography

SSTR: Somatostatin receptors

TAT: Targeted alpha therapy

TCMC: 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetamide

TRT: Targeted radionuclide therapy

UTEVA: Uranium and TEtraValents Actinide Resin

VCAM: Vascular cell adhesion molecule

Acknowledgments

Competing Interests

CMD is an employee of UZ Leuven. He is/has been a consultant for (fees received by institution): Sirtex, Advanced Accelerator Applications, Novartis, Ipsen, Terumo, PSI CRO, Immedica Pharma, Molecular Partners, Nuclear Research and consultancy, and ITM. His institution has received travel fees from: GE Healthcare, Sirtex. KG is an employee of UZ Leuven. She reports fees from Telix (consultant and speaker), Bayer (consultant and speaker), Novartis (consultant and speaker), Blue Earth Diagnostics (consultant), MSD (consultant), PSI CRO (consultant) and FullLife Technologies (consultant), outside of the submitted work. AC is a contracted researcher for Actinium Pharma, Novocure and Oncoinvent.

The other authors have declared that no competing interest exists.

References

1. Radchenko V, Morgenstern A, Jalilian AR, Ramogida CF, Cutler C, Duchemin C, et al. Production and Supply of α-Particle–Emitting Radionuclides for Targeted α-Therapy. J Nucl Med. 2021; 62: 1495-503.

2. Li RG, Stenberg VY, Larsen RH. An Experimental Generator for Production of High-Purity 212 Pb for Use in Radiopharmaceuticals. J Nucl Med. 2023; 64: 173-6.

3. Zimmermann R. Is 212 Pb Really Happening? The Post- 177 Lu/ 225 Ac Blockbuster? J Nucl Med. 2024; 65: 176-7.

4. McNeil BL, Robertson AKH, Fu W, Yang H, Hoehr C, Ramogida CF, et al. Production, purification, and radiolabeling of the 203Pb/212Pb theranostic pair. EJNMMI Radiopharm Chem. 2021; 6: 6.

5. Burkett BJ, Bartlett DJ, McGarrah PW, Lewis AR, Johnson DR, Berberoğlu K, et al. A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements. Radiol Imaging Cancer. 2023; 5: e220157.

6. Bruland ØS, Larsen RH, Baum RP, Juzeniene A. Editorial: Targeted alpha particle therapy in oncology. Front Med (Lausanne). 2023; 10: 1165747.

7. Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021; 385: 1091–103.

8. Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, et al. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024; 403: 2807-17.

9. Kassis AI. Therapeutic Radionuclides: Biophysical and Radiobiologic Principles. Semin Nucl Med. 2008; 38: 358-66.

10. Pouget JP, Constanzo J. Revisiting the Radiobiology of Targeted Alpha Therapy. Front Med (Lausanne). 2021; 8: 692436.

11. Eychenne R, Chérel M, Haddad F, Guérard F, Gestin J-F. Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The "Hopeful Eight." Pharmaceutics. 2021; 13: 906.

12. Tosato M, Favaretto C, Kleynhans J, Burgoyne AR, Gestin J-F, van der Meulen NP, et al. Alpha Atlas: Mapping global production of α-emitting radionuclides for targeted alpha therapy. Nucl Med Biol. 2024; 142-143: 108990.

13. Scaffidi-Muta JM, Abell AD. 212Pb in targeted radionuclide therapy: a review. EJNMMI Radiopharm Chem. 2025; 10: 34.

14. Westrøm S, Generalov R, Bønsdorff TB, Larsen RH. Preparation of 212Pb-labeled monoclonal antibody using a novel 224Ra-based generator solution. Nucl Med Biol. 2017; 51: 1-9.

15. Pibida L, Bergeron DE, Collins SM, Ivanov P, Cessna JT, Fitzgerald RP, et al. Absolute emission intensities of the gamma rays from the decay of 224Ra and 212Pb progenies and the half-life of the 212 Pb decay. Appl Radiat Isot. 2024; 205: 111171.

16. Napoli E, Stenberg VY, Juzeniene A, Hjellum GE, Bruland ØS, Larsen RH. Calibration of sodium iodide detectors and reentrant ionization chambers for 212Pb activity in different geometries by HPGe activity determined samples. Appl Radiat Isot. 2020; 166: 109362.

17. Bergeron DE, Cessna JT, Fitzgerald RP, Laureano-Pérez L, Pibida L, Zimmerman BE. Primary standardization of 212Pb activity by liquid scintillation counting. Appl Radiat Isot. 2022; 190: 110473.

18. Pretze M, Wendrich J, Hartmann H, Freudenberg R, Bundschuh RA, Kotzerke J, et al. Comparison of ZnS(Ag) Scintillator and Proportional Counter Tube for Alpha Detection in Thin-Layer Chromatography. Pharmaceuticals (Basel). 2025; 18: 26.

19. Kvassheim M, Revheim M-ER, Stokke C. Quantitative SPECT/CT imaging of lead-212: a phantom study. EJNMMI Phys. 2022; 9: 52.

20. Kvassheim M, Tornes AJK, Juzeniene A, Stokke C, Revheim M-ER. Imaging of 212Pb in mice with a clinical SPECT/CT. EJNMMI Phys. 2023; 10: 47.

21. Kästner D, Hartmann H, Freudenberg R, Pretze M, Brogsitter C, Schultz MK, et al. Gamma camera imaging characteristics of 203/212Pb as a theragnostic pair for targeted alpha therapy: a feasibility study. EJNMMI Phys. 2025; 12: 50.

22. Couturier O, Supiot S, Degraef-Mougin M, Faivre-Chauvet A, Carlier T, Chatal J-F, et al. Cancer radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med Mol Imaging. 2005; 32 :601-14.

23. McNeil BL, Mastroianni SA, McNeil SW, Zeisler S, Kumlin J, Borjian S, et al. Optimized production, purification, and radiolabeling of the 203Pb/212Pb theranostic pair for nuclear medicine. Sci Rep. 2023; 13: 10623.

24. Horlock PL, Thakur ML, Watson IA. Cyclotron produced lead-203. Postgrad Med J. 1975; 51: 751-4.

25. Nelson BJB, Wilson J, Andersson JD, Wuest F. Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications. Pharmaceuticals (Basel). 2023; 16: 1622.

26. Nelson BJB, Wilson J, Schultz MK, Andersson JD, Wuest F. High-yield cyclotron production of 203Pb using a sealed 205Tl solid target. Nucl Med Biol. 2023; 116–117: 108314.

27. Graves S, Li M, Lee D, Schultz MK. On the Use of 203Pb Imaging to Inform 212Pb Dosimetry for 203/212Pb Image-Guided Alpha-Particle Therapy for Cancer. In: Prasad V, Ed. Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum. Springer, Cham; 2024: 277-87.

28. Baidoo KE, Milenic DE, Brechbiel MW. Methodology for labeling proteins and peptides with lead-212 (212Pb). Nucl Med Biol. 2013; 40: 592–9.

29. Mirzadeh S, Kumar K, Gansow OA. The Chemical Fate of 212Bi-DOTA Formed by β - Decay of 212Pb(DOTA)2-***. Radiochim Acta. 1993; 60: 1-10.

30. Morimoto EM, Kahn M. Preparation of carrier-free lead-212 (thorium B). J Chem Educ. 1959; 36: 296.

31. Zucchini GL, Friedman AM. Isotopic generator for 212Pb and 212Bi. Int J Nucl Med Biol. 1982; 9: 83-4.

32. McAlister DR, Horwitz EP. Chromatographic generator systems for the actinides and natural decay series elements. Radiochim Acta. 2011; 99: 151-9.

33. Hassfjell S. A 212Pb generator based on a 228Th source. Appl Radiat Isot. 2001; 55: 433-9.

34. Kokov K V., Egorova B V., German MN, Klabukov ID, Krasheninnikov ME, Larkin-Kondrov AA, et al. 212Pb: Production Approaches and Targeted Therapy Applications. Pharmaceutics. 2022; 14: 189.

35. Atcher RW, Friedman AM, Hines JJ. An improved generator for the production of 212Pb and 212Bi from 224Ra. Int J Rad Appl Instrum A. 1988;39:283–6.

36. Narbutt J, Bilewicz A. Gamma emitting radiotracers 224Ra, 212Pb and 212Bi from natural thorium. Appl Radiat Isot. 1998; 49: 89-91.

37. Bartoś B, Lyczko K, Kasperek A, Krajewski S, Bilewicz A. Search of ligands suitable for 212Pb/212Bi *in vivo* generators. J Radioanal Nucl Chem. 2013; 295: 205-9.

38. Milenic DE, Baidoo KE, Brechbiel MW. Bench to Bedside: Stability Studies of GMP Produced Trastuzumab-TCMC in Support of a Clinical Trial. Pharmaceuticals (Basel). 2015; 8: 435-54.

39. Mirzadeh S. Generator-produced alpha-emitters. Appl Radiat Isot. 1998; 49: 345-9.

40. Howell RW, Azure MT, Narra VR, Rao D V. Relative biological effectiveness of alpha-particle emitters *in vivo* at low doses. Radiat Res. 1994; 137: 352-60.

41. Li M, Zhang X, Quinn TP, Lee D, Liu D, Kunkel F, et al. Automated cassette-based production of high specific activity 203/212Pb.peptide-based theranostic radiopharmaceuticals for image-guided radionuclide therapy for cancer. Appl Radiat Isot. 2017; 127: 52-60.

42. Gregory JN, Moorbath S. The diffusion of thoron in solids. Part II—the emanating power of barium salts of the fatty acids. Trans Faraday Soc. 1951; 47: 1064-72.

43. Norman JH, Wrasidlo WA, Mysels KJ. Method and generator for producing radioactive Lead-212. EP0466290A11. 1991. https://patents.google.com/patent/EP0466290A1/en

44. Hassfjell SP, Hoff P. A generator for production of 212Pb and 212Bi. Appl Radiat Isot. 1994; 45: 1021-5.

45. Boldyrev PP, Egorova B V., Kokov K V., Perminov YA, Proshin MA, Chuvilin DY. Physical and chemical processes on the 212Pb radionuclide production for nuclear medicine. J Phys Conf Ser, vol. 1099, Institute of Physics Publishing; 2018.

46. Pretze M, Hartmann H, Duchemin C, Stora T, Inzamam M, Kästner D, et al. Different 212Pb Generators and Its Radiation Safety Concerning 220Rn (Thoron) Emanation. Toxics. 2025; 13: 462.

47. Berckmans Y, Wouters R, Raskovic-Lovre Z, Van Mechelen S, Lindland K, Bonsdorff T, et al. Targeted Alpha Therapy of Ovarian Cancer with 212Pb-Labeled Anti-PTK7 Antibody: On-site 212Pb Production and Preclinical Insights. Nuc Med Biol. 2025; 150-151: 109570.

48. Pretze M, Michler E, Kästner D, Kunkel F, Sagastume EA, Schultz MK, et al. Lead-it-EAZY! GMP-compliant production of [212Pb]Pb-PSC-PEG2-TOC. EJNMMI Radiopharm Chem. 2024; 9: 81.

49. Hashimoto T, Komatsu S, Kido K, Sotobayashi T. Elution behaviour of alpha-recoil atoms into etchant and ovservation of their tracks on the mica surface. Nucl Instrum Methods. 1980; 178: 437-42.

50. Corroyer-Dulmont A, Valable S, Falzone N, Frelin-Labalme A-M, Tietz O, Toutain J, et al. VCAM-1 targeted alpha-particle therapy for early brain metastases. Neuro Oncol. 2020; 22: 357-68.

51. Makvandi M, Dupis E, Engle JW, Nortier FM, Fassbender ME, Simon S, et al. Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations. Target Oncol. 2018; 13: 189-203.

52. Máthé D, Szigeti K, Hegedűs H, Horváth I, Veres DS, Kovács B, et al. Production and *in vivo* imaging of 203Pb as a surrogate isotope for *in vivo* 212Pb internal absorbed dose studies. Appl Radiat Isot. 2016; 114: 1-6.

53. Li M, Sagastume EA, Lee D, McAlister D, DeGraffenreid AJ, Olewine KR, et al. 203/212Pb Theranostic Radiopharmaceuticals for Image-guided Radionuclide Therapy for Cancer. Curr Med Chem. 2020; 27: 7003–31.

54. Saini S, Bartels JL, Appiah J-PK, Rider JH, Baumhover N, Schultz MK, et al. Optimized Methods for the Production of High-Purity 203Pb Using Electroplated Thallium Targets. J Nucl Med. 2023; 64: 1791-7.

55. Li M, Baumhover NJ, Liu D, Cagle BS, Boschetti F, Paulin G, et al. Preclinical Evaluation of a Lead Specific Chelator (PSC) Conjugated to Radiopeptides for 203Pb and 212Pb-Based Theranostics. Pharmaceutics. 2023; 15: 414.

56. Chapeau D, Koustoulidou S, Handula M, Beekman S, de Ridder C, Stuurman D, et al. 212Pb.Pb-eSOMA-01: A Promising Radioligand for Targeted Alpha Therapy of Neuroendocrine Tumors. Pharmaceuticals (Basel). 2023; 16: 985.

57. Sounalet T, Guertin A, Haddad F, Kamalakannan K, Nigron E. Production of 203Pb from enriched 205Tl using deuteron beams. Appl Radiat Isot. 2024; 205: 111190.

58. Brady F, Clark JC, Luthra SK. Building on a 50-year legacy of the MRC Cyclotron Unit: the Hammersmith radiochemistry pioneering journey. J Labelled Comp Radiopharm. 2007; 50: 903-26.

59. Shannon RD. Revised effective ionic radii and systematic studies of interatomic distances in halides and chalcogenides. Acta Crystallographica Section A. 1976; 32: 751-67.

60. Martell AE, Hancock RD. Metal Complexes in Aqueous Solutions. Berlin/Heidelberg, Germany: Springer science & Business Media; 1996.

61. Blei MK, Waurick L, Reissig F, Kopka K, Stumpf T, Drobot B, et al. Equilibrium Thermodynamics of Macropa Complexes with Selected Metal Isotopes of Radiopharmaceutical Interest. Inorg Chem. 2023; 62: 20699-709.

62. Cheng Y, Sequeira SM, Malinina L, Tereshko V, Söllner TH, Patel DJ. Crystallographic identification of Ca 2+ and Sr 2+ coordination sites in synaptotagmin I C 2 B domain. Protein Sci. 2004; 13: 2665-72.

63. Tanui HK, Nnaji N, Mapolie SF, Hussein AA, Luckay RC. Crystal structure of lead(II) with the flavonoid morin elucidating evidence of the "inert pair effect" as well as a computational study. J Mol Struct. 2024; 1307: 137993.

64. Drago RS. Thermodynamic Evaluation of the Inert Pair Effect. J Phys Chem. 1958;62:353–7.

65. Davidovich RL, Stavila V, Whitmire KH. Stereochemistry of lead(II) complexes containing sulfur and selenium donor atom ligands. Coord Chem Rev. 2010; 254: 2193-226.

66. Cecconi F, Ghilardi CA, Midollini S, Orlandini A. Lone pair activity in lead(II) compounds. X-ray structure of the dimeric complex [(trenMe6) Pb(O2CCH3)]2(BPh4)2, trenMe6=N(CH2CH2N(CH3)2)3. Inorganica Chim Acta. 2000; 308: 135-8.

67. Metz Bernard, Weiss Raymond. Highly coordinated lead. Crystal and molecular structure of (4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo[8.8.8] hexacosane)lead(II) thiocyanate. Inorg Chem. 1974; 13: 2094-8.

68. Abu-Dari K, Hahn FE, Raymond KN. Lead sequestering agents. 1. Synthesis, physical properties, and structures of lead thiohydroxamato complexes. J Am Chem Soc. 1990; 112: 1519-24.

69. Cristidis P, Tossidis I, Hondroudis C. Crystal structure and spectra of the mixed-ligands complex 1-(2-thenoyl)-2-1 ′ (2 ″ -pyridyl)- ethylidene.hydrazino-acetato lead(II). Z Kristallogr Cryst Mater. 1994; 209: 607-10.

70. Nazarenko AY, Rusanov EB. Synthesis and crystal structure of lead thiocyanate complexes with 18-crown-6 and two isomers of dicyclohexane-18-crown-6. Polyhedron. 1994; 13: 2549-53.

71. Nugent JW, Lee H-S, Reibenspies JH, Hancock RD. Spectroscopic, structural, and thermodynamic aspects of the stereochemically active lone pair on lead(II): Structure of the lead(II) dota complex. Polyhedron. 2015 ;91: 120-7.

72. Shimoni-Livny L, Glusker JP, Bock CW. Lone Pair Functionality in Divalent Lead Compounds. Inorg Chem. 1998; 37: 1853-67.

73. McNeil BL, Kadassery KJ, McDonagh AW, Zhou W, Schaffer P, Wilson JJ, et al. Evaluation of the Effect of Macrocyclic Ring Size on [203Pb]Pb(II) Complex Stability in Pyridyl-Containing Chelators. Inorg Chem. 2022; 61: 9638-49.

74. Cuenot F, Meyer M, Espinosa E, Bucaille A, Burgat R, Guilard R, et al. New Insights into the Complexation of Lead(II) by 1,4,7,10-Tetrakis(carbamoylmethyl)-1,4,7,10-tetraazacyclododecane (DOTAM): Structural, Thermodynamic, and Kinetic Studies. Eur J Inorg Chem. 2008; 2008: 267-83.

75. Hancock RD, Salim Shaikjee M, Dobson SM, Boeyens JCA. The Stereochemical activity or non-activity of the 'Inert' pair of electrons on lead(II) in relation to its complex stability and structural properties. Some considerations in ligand design. Inorganica Chim Acta. 1988; 154: 229-38.

76. Tosato M, Lazzari L, Marco V Di. Revisiting Lead(II)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic Acid Coordination Chemistry in Aqueous Solutions: Evidence of an Underestimated Thermodynamic Stability. ACS Omega. 2022; 7: 15596-602.

77. Saidi A, Stallons TA, Wong AG, Schatzmann AT, Soysal U, Torgu JJ. Side-by-Side Comparison of the *In Vivo* Performance of [212Pb]Pb-DOTAMTATE and Other SSTR2-Targeting Compounds. J Nucl Med. 2025; 66: 391-97.

78. Tosato M, Randhawa P, Lazzari L, McNeil BL, Dalla Tiezza M, Zanoni G, et al. Tuning the Softness of the Pendant Arms and the Polyazamacrocyclic Backbone to Chelate the 203Pb/ 212Pb Theranostic Pair. Inorg Chem. 2024; 63: 1745-58.

79. Hierlmeier I, Randhawa P, McNeil BL, Oliveri E, Maus S, Radchenko V, et al. Radiochemistry of cyclen-derived chelators comprising five-membered azaheterocyclic arms with 212Pb2+, 213Bi3+, and 225Ac3. Nucl Med Biol. 2025;146-147:109034.

80. Ingham A, Kostelnik TI, McNeil BL, Patrick BO, Choudhary N, Jaraquemada-Peláez M de G, et al. Getting a lead on Pb2+ -amide chelators for 203/212Pb radiopharmaceuticals. Dalton Trans. 2021; 50: 11579-95.

81. Plichta KA, Buatti JM. The Emerging Potential of Lead-212 Theranostics. Hematol Oncol Clin North Am. 2025; 39: 221-36.

82. Kozempel J, Mokhodoeva O, Vlk M. Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from *In Vivo* Generators. Molecules. 2018; 23: 581.

83. Su F-M, Beaumier P, Axworthy D, Atcher R, Fritzberg A. Pretargeted radioimmunotherapy in tumored mice using an *in vivo* 212Pb/212Bi generator. Nucl Med Biol. 2005; 32: 741-7.

84. Maaland AF, Saidi A, Torgue J, Heyerdahl H, Stallons TAR, Kolstad A, et al. Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin's lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003. PLoS One. 2020; 15 :e0230526.

85. Yong K, Brechbiel M. Application of 212Pb for Targeted α-particle Therapy (TAT): Pre-clinical and Mechanistic Understanding through to Clinical Translation. AIMS Med Sci. 2015; 2: 228-45.

86. Milenic D, Molinolo A, Solivella M, Banaga E, Torgue J, Besnainou S, et al. Toxicological Studies of 212Pb Intravenously or Intraperitoneally Injected into Mice for a Phase 1 Trial. Pharmaceuticals (Basel). 2015; 8: 416-34.

87. Milenic DE, Kim Y-S, Baidoo KE, Wong KJ, Barkley R, Delgado J, et al. Exploration of a F(ab′)2 Fragment as the Targeting Agent of α -Radiation Therapy: A Comparison of the Therapeutic Benefit of Intraperitoneal and Intravenous Administered Radioimmunotherapy. Cancer Biother Radiopharm. 2018; 33: 182-93.

88. Li RG, Lindland K, Bønsdorff TB, Westrøm S, Larsen RH. A Novel Single-Step-Labeled 212Pb-CaCO3 Microparticle for Internal Alpha Therapy: Preparation, Stability, and Preclinical Data from Mice. Materials. 2021; 14: 7130.

89. Alam MR, Singh SB, Thapaliya S, Shrestha S, Deo S, Khanal K. A Review of 177Lutetium-PSMA and 225Actinium-PSMA as Emerging Theranostic Agents in Prostate Cancer. Cureus. 2022; 14: e29369.

90. Stenberg VY, Juzeniene A, Bruland ØS, Larsen RH. *In situ* Generated 212Pb-PSMA Ligand in a 224Ra-Solution for Dual Targeting of Prostate Cancer Sclerotic Stroma and PSMA-Positive Cells. Curr Radiopharm. 2020; 13: 130-41.

91. Stenberg VY, Juzeniene A, Chen Q, Yang X, Bruland ØS, Larsen RH. Preparation of the alpha-emitting prostate-specific membrane antigen targeted radioligand [212Pb]Pb-NG001 for prostate cancer. J Labelled Comp Radiopharm. 2020; 63:1 29-43.

92. Stenberg VY, Tornes AJK, Nilsen HR, Revheim M-E, Bruland ØS, Larsen RH, et al. Factors Influencing the Therapeutic Efficacy of the PSMA Targeting Radioligand 212Pb-NG001. Cancers (Basel). 2022; 14: 2784.

93. Banerjee SR, Minn I, Kumar V, Josefsson A, Lisok A, Brummet M, et al. Preclinical Evaluation of 203/212Pb-Labeled Low-Molecular-Weight Compounds for Targeted Radiopharmaceutical Therapy of Prostate Cancer. J Nucl Med. 2020; 61: 80-8.

94. dos Santos JC, Schäfer M, Bauder-Wüst U, Lehnert W, Leotta K, Morgenstern A, et al. Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands: bringing "the lead" into PSMA-targeted alpha therapy? Eur J Nucl Med Mol Imaging. 2019; 46: 1081-91.

95. Fallah J, Agrawal S, Gittleman H, Fiero MH, Subramaniam S, John C, et al. FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 2023; 29: 1651-7.

96. Kim YJ, Kim Y. Therapeutic Responses and Survival Effects of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer. Clin Nucl Med. 2018; 43: 728-34.

97. Berner K, Hernes E, Kvassheim M, Revheim M-E, Bastiansen J, Selboe S, et al. First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen–Targeted 212Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2025; 66: 732-8.

98. Griffiths MR, Pattison DA, Latter M, Kuan K, Taylor S, Tieu W, et al. First-in-Human 212Pb-PSMA–Targeted α-Therapy SPECT/CT Imaging in a Patient with Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2024; 65: 664.

99. McConathy J, Dhawan M, Goenka A, Moy R, Menda Y, Chasen B, et al. 177Lu-FAP-2286 in patients with advanced or metastatic solid tumors: Initial data from a phase 1/2 study investigating safety, pharmacokinetics, dosimetry, and preliminary antitumor activity (LuMIERE). J Nucl Med. 2022; 63: 2271.

100. Domanska UM, Kruizinga RC, Nagengast WB, Timmer-Bosscha H, Huls G, de Vries EGE, et al. A review on CXCR4/CXCL12 axis in oncology: No place to hide. Eur J Cancer. 2013; 49: 219-30.

101. Bauckneht M, Filippi L. Pentixather: paving the way for radioligand therapy in oncohematology. Expert Rev Anticancer Ther. 2024; 24: 205-9.

102. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017; 376: 125-35.

103. Ahmadi Bidakhvidi N, Goffin K, Dekervel J, Baete K, Nackaerts K, Clement P, et al. Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization Strategies. Cancers (Basel). 2021; 14: 129.

104. Stallons TAR, Saidi A, Tworowska I, Delpassand ES, Torgue JJ. Preclinical Investigation of 212Pb-DOTAMTATE for Peptide Receptor Radionuclide Therapy in a Neuroendocrine Tumor Model. Mol Cancer Ther. 2019; 18: 1012-21.

105. Pretze M, Michler E, Runge R, Wetzig K, Tietze K, Brandt F, et al. Influence of the Molar Activity of 203/212Pb-PSC-PEG2-TOC on Somatostatin Receptor Type 2-Binding and Cell Uptake. Pharmaceuticals (Basel). 2023; 16: 1605.

106. Delpassand ES, Tworowska I, Esfandiari R, Torgue J, Hurt J, Shafie A, et al. Targeted α -Emitter Therapy with 212Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial. J Nucl Med. 2022; 63: 1326-33.

107. Strosberg JR, Naqvi S, Cohn AL, Delpassand ES, Wagner VJ, Tworowska I, et al. Safety, tolerability and efficacy of 212Pb-DOTAMTATE as a targeted alpha therapy for subjects with unresectable or metastatic somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors (SSTR+ GEP-NETs): A phase 2 study. J Clin Oncol. 2024; 42:4020.

108. Strosberg JR, Naqvi S, Cohn A, Delpassand E, Wagner VJ, Tworowska I, et al. 1034MO Long-term follow-up of peptide receptor radionuclide therapy (PRRT)-naïve patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with targeted alpha therapy 212Pb-DOTAMTATE in the phase II ALPHAMEDIX 02 trial. Ann Oncol. 2025; 36: S671.

109. Strosberg JR, Naqvi S, Cohn A, Delpassand E, Wagner VJ, Tworowska I, et al. 1032O Efficacy and safety of targeted alpha therapy 212Pb-DOTAMTATE in patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) previously treated with peptide receptor radionuclide therapy (PRRT): Results of a phase II study. Ann Oncol. 2025; 36: S670.

110. Michler E, Kästner D, Brogsitter C, Pretze M, Hartmann H, Freudenberg R, et al. First-in-human SPECT/CT imaging of [212Pb]Pb-VMT-α-NET in a patient with metastatic neuroendocrine tumor. Eur J Nucl Med Mol Imaging. 2023; 51: 1490-92.

111. Graves S, Bushnell D, Schultz M, Bodeker K, Dillon J, Menda Y. 212Pb-VMT-α-NET α-PRRT planning based on 203Pb-VMT-α-NET predictive dosimetry. J Nucl Med. 2024; 65: 242110.

112. Michler E, Kästner D, Pretze M, Hartmann H, Freudenberg R, Schultz MK, et al. [203/212Pb]Pb-VMT-α-NET as a novel theranostic agent for targeted alpha radiotherapy—first clinical experience. Eur J Nucl Med Mol Imaging. 2025; 52: 4171-83.

113. Halfdanarson TR, Wahl R, Solnes L, Balaraman S, Sibley G, Mancini B, et al. 1033MO [212Pb]VMT-α-NET targeted alpha-particle therapy (TAT) for advanced somatostatin receptor 2-positive (SSTR2+) neuroendocrine tumours (NETs): Mature safety and preliminary efficacy for enrollment from dose-finding cohorts 1 and 2 (n=44). Ann Oncol. 2025; 36: S670.

114. Miao Y, Hylarides M, Fisher DR, Shelton T, Moore H, Wester DW, et al. Melanoma Therapy via Peptide-Targeted α-Radiation. Clin Cancer Res. 2005; 11: 5616-21.

115. Miao Y, Figueroa SD, Fisher DR, Moore HA, Testa RF, Hoffman TJ, et al. 203=Pb-Labeled α-Melanocyte–Stimulating Hormone Peptide as an Imaging Probe for Melanoma Detection. J Nucl Med. 2008; 49: 823-9.

116. Yang J, Xu J, Cheuy L, Gonzalez R, Fisher DR, Miao Y. Evaluation of a Novel Pb-203-Labeled Lactam-Cyclized Alpha-Melanocyte-Stimulating Hormone Peptide for Melanoma Targeting. Mol Pharm. 2019; 16: 1694-702.

117. Li M, Liu D, Lee D, Cheng Y, Baumhover NJ, Marks BM, et al. Targeted Alpha-Particle Radiotherapy and Immune Checkpoint Inhibitors Induces Cooperative Inhibition on Tumor Growth of Malignant Melanoma. Cancers (Basel). 2021; 13: 3676.

118. Johnson G, Block M, Hruska C, Pandey M, Paulsen A, Kemp B, et al. Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy (TIMAR) Trial. J Nucl Med. 2023; 64: P378.

119. Morris ZS, Puhlmann M, Johnson F, Hanna A, Cho SY. A phase I/IIa of [212Pb]VMT01 targeted a-particle therapy for unresectable or metastatic melanoma. J Clin Oncol. 2024; 42: TPS9610.

120. Perspective Therapeutics. Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma. Press Release. 2024.

121. Mansi R, Nock BA, Dalm SU, Busstra MB, van Weerden WM, Maina T. Radiolabeled Bombesin Analogs. Cancers (Basel). 2021; 13: 5766.

122. Okoye N, Rold T, Berendzen A, Zhang X, White R, Schultz M, et al. Targeting the BB2 receptor in prostate cancer using a Pb-203 labeled peptide. J Nucl Med. 2017; 58: 321.

123. Rold T, Okoye N, Devanny E, Berendzen A, Dresser T, Quinn T, et al. Pb-203/Pb-212 Evaluation as Theranostic Pair for Prostate Cancer Detection, Monitoring, and Treatment. J Nucl Med. 2020; 61: 229.

124. Iqbal N, Iqbal N. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biol Int. 2014; 2014: 1-9.

125. Horak E, Hartmann F, Garmestani K, Wu C, Brechbiel M, Gansow OA, et al. Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1. J Nucl Med. 1997; 38: 1944-50.

126. Milenic DE, Garmestani K, Brady ED, Albert PS, Ma D, Abdulla A, et al. α-Particle Radioimmunotherapy of Disseminated Peritoneal Disease Using a 212Pb-Labeled Radioimmunoconjugate Targeting HER2. Cancer Biother Radiopharm. 2005; 20: 557-68.

127. Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW. (212)Pb-Radioimmunotherapy Induces G(2) Cell-Cycle Arrest and Delays DNA Damage Repair in Tumor Xenografts in a Model for Disseminated Intraperitoneal Disease. Mol Cancer Ther. 2012; 11: 639–48.

128. Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW. Sensitization of Tumor to 212Pb Radioimmunotherapy by Gemcitabine Involves Initial Abrogation of G2 Arrest and Blocked DNA Damage Repair by Interference with Rad51. Int J Radiat Oncol Biol Phys. 2013; 85: 1119-26.

129. Milenic DE, Garmestani K, Brady ED, Albert PS, Abdulla A, Flynn J, et al. Potentiation of High-LET Radiation by Gemcitabine: Targeting HER2 with Trastuzumab to Treat Disseminated Peritoneal Disease. Clin Cancer Res. 2007; 13: 1926–35.

130. Milenic DE, Garmestani K, Brady ED, Baidoo KE, Albert PS, Wong KJ, et al. Multimodality Therapy: Potentiation of High Linear Energy Transfer Radiation with Paclitaxel for the Treatment of Disseminated Peritoneal Disease. Clin Cancer Res. 2008;14: 5108-15.

131. Milenic DE, Baidoo KE, Shih JH, Wong KJ, Brechbiel MW. Evaluation of Platinum Chemotherapy in Combination with HER2-Targeted α-Particle Radiation. Cancer Biother Radiopharm. 2013; 28: 441-9.

132. Tan Z, Chen P, Schneider N, Glover S, Cui L, Torgue J, et al. Significant systemic therapeutic effects of high-LET immunoradiation by 212Pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice. Int J Oncol. 2012; 40: 1881-8.

133. Kasten BB, Arend RC, Katre AA, Kim H, Fan J, Ferrone S, et al. B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models. Nucl Med Biol. 2017; 47: 23-30.

134. Meredith RF, Torgue J, Azure MT, Shen S, Saddekni S, Banaga E, et al. Pharmacokinetics and Imaging of 212 Pb-TCMC-Trastuzumab After Intraperitoneal Administration in Ovarian Cancer Patients. Cancer Biother Radiopharm. 2014 ;29: 12-7.

135. Meredith R, Torgue J, Shen S, Fisher DR, Banaga E, Bunch P, et al. Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumab. J Nucl Med. 2014; 55: 1636-42.

136. Meredith RF, Torgue JJ, Rozgaja TA, Banaga EP, Bunch PW, Alvarez RD, et al. Safety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With 212Pb-TCMC-Trastuzumab. Am J Clin Oncol. 2018; 41: 716-21.

137. Milenic DE, Baidoo KE, Kim Y-S, Brechbiel MW. Evaluation of cetuximab as a candidate for targeted α-particle radiation therapy of HER1-positive disseminated intraperitoneal disease. MAbs. 2015; 7: 255-64.

138. Milenic DE, Baidoo KE, Kim Y-S, Barkley R, Brechbiel MW. Targeted α-Particle Radiation Therapy of HER1-Positive Disseminated Intraperitoneal Disease: An Investigation of the Human Anti-EGFR Monoclonal Antibody, Panitumumab. Transl Oncol. 2017; 10: 535-45.

139. Durand-Panteix S, Monteil J, Sage M, Garot A, Clavel M, Saidi A, et al. Preclinical study of 212Pb alpha-radioimmunotherapy targeting CD20 in non-Hodgkin lymphoma. Br J Cancer. 2021; 125: 1657-65.

140. Quelven I, Monteil J, Sage M, Saidi A, Mounier J, Bayout A, et al. 212Pb α-Radioimmunotherapy Targeting CD38 in Multiple Myeloma: A Preclinical Study. J Nucl Med. 2020; 61: 1058-65.

141. Jiao R, Allen KJH, Malo ME, Yilmaz O, Wilson J, Nelson BJB, et al. A Theranostic Approach to Imaging and Treating Melanoma with 203Pb/212Pb-Labeled Antibody Targeting Melanin. Cancers (Basel). 2023; 15: 3856.

142. Kasten BB, Gangrade A, Kim H, Fan J, Ferrone S, Ferrone CR, et al. 212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models. Nucl Med Biol. 2018; 58: 67-73.

143. Kasten B, Oliver P, Kim H, Fan J, Ferrone S, Zinn K, et al. 212Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models. Int J Mol Sci. 2018; 19: 925.

144. Li J, Huang T, Hua J, Wang Q, Su Y, Chen P, et al. CD46 targeted 212Pb alpha particle radioimmunotherapy for prostate cancer treatment. J Exp Clin Cancer Res. 2023; 42: 61.

145. Tornes AJK, Stenberg VY, Larsen RH, Bruland ØS, Revheim M-E, Juzeniene A. Targeted alpha therapy with the 224Ra/212Pb-TCMC-TP-3 dual alpha solution in a multicellular tumor spheroid model of osteosarcoma. Front Med (Lausanne). 2022; 9: 1058863.

146. Lindland K, Malenge MM, Li RG, Wouters R, Bønsdorff TB, Juzeniene A, et al. Antigen targeting and anti-tumor activity of a novel anti-CD146 212Pb internalizing alpha-radioimmunoconjugate against malignant peritoneal mesothelioma. Sci Rep. 2024; 14: 25941.

147. Lindland K, Westrøm S, Dragovic SM, Li RGong, Malenge MMasitsa, Ho B, et al. Preclinical Evaluation of PTK7-Targeted Radionuclide Therapy. Mol Cancer Ther. 2025; 24: 1415-27.

148. Shah MA, Zhang X, Rossin R, Robillard MS, Fisher DR, Bueltmann T, et al. Metal-Free Cycloaddition Chemistry Driven Pretargeted Radioimmunotherapy Using α-Particle Radiation. Bioconjug Chem. 2017; 28: 3007-15.

149. Bauer D, Carter LM, Atmane MI, De Gregorio R, Michel A, Kaminsky S, et al. 212Pb-Pretargeted Theranostics for Pancreatic Cancer. J Nucl Med. 2024; 65: 109-16.

150. Ashcroft JM, Tsyboulski DA, Hartman KB, Zakharian TY, Marks JW, Weisman RB, et al. Fullerene (C60) immunoconjugates: interaction of water-soluble C60 derivatives with the murine anti-gp240 melanoma antibody. Chem Commun. 2006; 2006: 3004–6.

151. Shultz MD, Duchamp JC, Wilson JD, Shu CY, Ge J, Zhang J, et al. Encapsulation of a Radiolabeled Cluster Inside a Fullerene Cage, 177LuxLu(3-x)N@C80: An Interleukin-13 Conjugated Radiolabeled Metallofullerene Platform. J Am Chem Soc. 2010; 132: 4980-1.

152. Large DE, Soucy JR, Hebert J, Auguste DT. Advances in Receptor-Mediated, Tumor-Targeted Drug Delivery. Adv Ther (Weinh). 2019; 2: 1800091.

153. Large DE, Abdelmessih RG, Fink EA, Auguste DT. Liposome composition in drug delivery design, synthesis, characterization, and clinical application. Adv Drug Deliv Rev. 2021; 176: 113851.

154. Kleynhans J, Sathekge M, Ebenhan T. Obstacles and Recommendations for Clinical Translation of Nanoparticle System-Based Targeted Alpha-Particle Therapy. Materials. 2021; 14: 4784.

155. Kerr CP, Jin WJ, Liu P, Grudzinski JJ, Ferreira CA, Rojas HC, et al. Priming versus propagating: distinct immune effects of an alpha- versus beta-particle emitting radiopharmaceutical when combined with immune checkpoint inhibition 2024; [Preprint]. DOI: 10.1101/2024.12.26.630430.

156. Kruijff RM de, Raavé R, Kip A, Molkenboer-Kuenen J, Morgenstern A, Bruchertseifer F, et al. The in vivo fate of 225Ac daughter nuclides using polymersomes as a model carrier. Sci Rep. 2019; 9: 11671.

157. Edem PE, Fonslet J, Kjær A, Herth M, Severin G. In Vivo Radionuclide Generators for Diagnostics and Therapy. Bioinorg Chem Appl. 2016; 2016:6148357.

158. Kleinendorst SC, Hooijmans CR, Muselaers S, Oosterwijk E, Konijnenberg M, Heskamp S, et al. Efficacy of combined targeted radionuclide therapy and immune checkpoint Inhibition in animal tumour models: a systematic review and meta-analysis of the literature. Eur J Nucl Med Mol Imaging. 2025; 52: 4735-51.